PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
7142708-5	1982	NK activity against YAC-1 tumor targets was reduced 1 mo after the first pristane injection and remained depressed for at least 3 mo.	pristane	73-81	ADP-ribosyltransferase 1	Mus musculus	20-25
6153226-1	1980	The ability of alpha-fetoprotein (AFP), derived from mouse amniotic fluid, to alter qualitative and quantitative characteristics of pristane-induced plasmacytomas and the carcinogenic action of 3-methylcholanthrene (MCA) and 7,12-dimethylbenz]a[-anthracene (DMBA) was studied and compared to analogous treatment with murine albumin and transferrin in BALB/c mice.	pristane	132-140	alpha fetoprotein	Mus musculus	15-32
6153226-1	1980	The ability of alpha-fetoprotein (AFP), derived from mouse amniotic fluid, to alter qualitative and quantitative characteristics of pristane-induced plasmacytomas and the carcinogenic action of 3-methylcholanthrene (MCA) and 7,12-dimethylbenz]a[-anthracene (DMBA) was studied and compared to analogous treatment with murine albumin and transferrin in BALB/c mice.	pristane	132-140	alpha fetoprotein	Mus musculus	34-37
6153226-4	1980	In contrast AFP, but neither albumin nor transferrin, accelerated the appearance of plasmacytomas in pristane-primed BALB/c mice.	pristane	101-109	alpha fetoprotein	Mus musculus	12-15
32776428-4	2021	While signaling through the type I interferon receptor (IFNAR) is implicated in pristane-induced lupus ("interferon signature"), the studies of Zhao, et al.	pristane	80-88	interferon (alpha and beta) receptor 1	Mus musculus	56-61
33894002-9	2021	In SLE model, in WT mice, 6h after pristane injection we observed decline of A1 R mRNA levels, that was in parallel to lymphocytes reduction.	pristane	35-43	adenosine A1 receptor	Mus musculus	77-81
33894002-10	2021	Following pristane 43% of A1 R-KO mice suffered from lupus-like disease while WT mice remained without any sign of disease at 36 weeks.	pristane	10-18	adenosine A1 receptor	Mus musculus	26-30
33444326-5	2021	We deleted the slc15a4 gene in C57BL/6, NZB, and NZW mice and found that pristane-challenged slc15a4-/- mice in the C57BL/6 background and lupus prone slc15a4-/- NZB/W F1 mice were both completely protected from lupus like disease.	pristane	73-81	solute carrier family 15, member 4	Mus musculus	15-22
33444326-5	2021	We deleted the slc15a4 gene in C57BL/6, NZB, and NZW mice and found that pristane-challenged slc15a4-/- mice in the C57BL/6 background and lupus prone slc15a4-/- NZB/W F1 mice were both completely protected from lupus like disease.	pristane	73-81	solute carrier family 15, member 4	Mus musculus	93-100
33444326-5	2021	We deleted the slc15a4 gene in C57BL/6, NZB, and NZW mice and found that pristane-challenged slc15a4-/- mice in the C57BL/6 background and lupus prone slc15a4-/- NZB/W F1 mice were both completely protected from lupus like disease.	pristane	73-81	solute carrier family 15, member 4	Mus musculus	93-100
33827645-7	2021	In a pristane-induced lupus model, Lf-/- mice had more serious symptoms than WT mice, whereas lactoferrin treatment alleviated these symptoms.	pristane	5-13	lactotransferrin	Mus musculus	94-105
33841441-6	2021	Presence of antibodies against HU1 in pristane-induced mice aggravated lupus nephritis, although these antibodies also attenuated bacterial biofilm formation.	pristane	38-46	homeobox B5	Homo sapiens	31-34
33559374-4	2021	RESULTS: The absence of Aim2 but not Asc led to enhanced SLE in pristane-injected mice.	pristane	64-72	absent in melanoma 2	Mus musculus	24-28
33559374-6	2021	Adaptive immune cells were also involved in the glomerular lesions of Aim2-/- mice after pristane challenge.	pristane	89-97	absent in melanoma 2	Mus musculus	70-74
33072095-3	2020	To gain insight into this biology, we interrogated the role of oxyguanine glycosylase 1 (OGG1), which repairs oxidized guanine 8-Oxo-2"-deoxyguanosine (8-OH-dG), in the pristane-induced mouse model of SLE.	pristane	169-177	8-oxoguanine DNA-glycosylase 1	Mus musculus	63-87
32692482-6	2020	A model of pristane-induced lung injury in GSDMD-/- mice (n = 7), with WT mice as controls (n = 10), was used to confirm the pulmonary phenotype.	pristane	11-19	gasdermin D	Mus musculus	43-48
32866644-7	2020	In pristane-induced arthritis (PIA) rat model, Derl3 was up-regulated in synovial tissue and disease was attenuated after intraarticular injection of siDerl3.	pristane	3-11	derlin 3	Rattus norvegicus	47-52
32646856-6	2020	Both neutralization of LCN2 in MRL/lpr mice and genetic depletion of LCN2 in pristane-induced lupus mice greatly ameliorate nephritis.	pristane	77-85	lipocalin 2	Mus musculus	69-73
33079487-5	2020	A pristane-induced murine lupus model was used to further demonstrate the effects of IL-38 on cytokines in vivo and discuss the significance of IL-38 in lupus development.	pristane	2-10	interleukin 1 family member 10	Homo sapiens	85-90
32500632-7	2020	RESULTS: RNA-sequencing analysis revealed increased expression of genes regulated by the transcription factor Nrf2 in NCM from MO- vs. pristane-treated mice and in NCM vs. CM.	pristane	135-143	nuclear factor, erythroid derived 2, like 2	Mus musculus	110-114
33072095-3	2020	To gain insight into this biology, we interrogated the role of oxyguanine glycosylase 1 (OGG1), which repairs oxidized guanine 8-Oxo-2"-deoxyguanosine (8-OH-dG), in the pristane-induced mouse model of SLE.	pristane	169-177	8-oxoguanine DNA-glycosylase 1	Mus musculus	89-93
33072095-4	2020	Ogg1 -/- mice showed increased influx of Ly6Chi monocytes into the peritoneal cavity and enhanced IFN-driven gene expression in response to short-term exposure to pristane.	pristane	163-171	8-oxoguanine DNA-glycosylase 1	Mus musculus	0-4
33072095-5	2020	Loss of Ogg1 was associated with increased auto-antibodies (anti-dsDNA and anti-RNP), higher total IgG, and expression of interferon stimulated genes (ISG) to longer exposure to pristane, accompanied by aggravated skin pathology such as hair loss, thicker epidermis, and increased deposition of IgG in skin lesions.	pristane	178-186	8-oxoguanine DNA-glycosylase 1	Mus musculus	8-12
32700597-5	2020	Syk abundance in FcgRIIb-/- mice was higher than in pristane mice, possibly due to several Syk activators (anti-dsDNA, LPS and BG), and Syk inhibitor-attenuated proteinuria and serum cytokines only in FcgRIIb-/- mice.	pristane	52-60	spleen tyrosine kinase	Mus musculus	0-3
32237065-6	2020	In addition, alpha2AP deficiency attenuated the pristane-induced glomerular cell proliferation, mesangial matrix expansion, collagen production, fibrin deposition, immunoglobulin G deposition, and proinflammatory cytokine production in the model mice.	pristane	48-56	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	13-21
31171475-8	2019	Moreover, REGgamma-/- mice also expedites Pristane-induced lupus.	pristane	42-50	proteaseome (prosome, macropain) activator subunit 3 (PA28 gamma, Ki)	Mus musculus	10-18
32401403-4	2020	The T cell mediated autoimmune diseases such as pristane induced arthritis (PIA) and autoimmune encephalomyelitis (EAE) in rats model were profoundly ameliorated by treating with the specific G protein couple receptors 120 (GPR120) stimuli Omega-3 fatty acids (omega-3 FAs).	pristane	48-56	free fatty acid receptor 4	Rattus norvegicus	224-230
32249615-3	2020	In this study, we systematically evaluated the changes in B cell activation induced by the Xbp1 splicing inhibitor STF083010 in a pristane-induced lupus mouse model.	pristane	130-138	X-box binding protein 1	Mus musculus	91-95
32345366-4	2020	RESULTS: Rats subjected to whole-body irradiation and injected with CD4+ T cells from lymph nodes of pristane-injected donors developed chronic arthritis that lasted for more than 4 months, whereas T cells from the spleen only induced acute disease.	pristane	101-109	Cd4 molecule	Rattus norvegicus	68-71
31971297-5	2020	In the pristane-induced murine lupus model, pharmacological inhibition of SphK1 or its genetic deletion markedly decreased the IFN signature, pDC activation, and glomerulonephritis.	pristane	7-15	sphingosine kinase 1	Mus musculus	74-79
31601823-0	2019	Galectin-3 orchestrates the histology of mesentery and protects liver during lupus-like syndrome induced by pristane.	pristane	108-116	lectin, galactose binding, soluble 3	Mus musculus	0-10
31601823-4	2019	Here, we used pristane (2,6,10,14-tetramethylpentadecane) to induce lupus-like syndrome in Lgals3-/- and Lgals3+/+ BALB/c mice.	pristane	14-22	lectin, galactose binding, soluble 3	Mus musculus	91-97
31601823-4	2019	Here, we used pristane (2,6,10,14-tetramethylpentadecane) to induce lupus-like syndrome in Lgals3-/- and Lgals3+/+ BALB/c mice.	pristane	14-22	lectin, galactose binding, soluble 3	Mus musculus	105-111
31601823-4	2019	Here, we used pristane (2,6,10,14-tetramethylpentadecane) to induce lupus-like syndrome in Lgals3-/- and Lgals3+/+ BALB/c mice.	pristane	24-56	lectin, galactose binding, soluble 3	Mus musculus	91-97
31601823-4	2019	Here, we used pristane (2,6,10,14-tetramethylpentadecane) to induce lupus-like syndrome in Lgals3-/- and Lgals3+/+ BALB/c mice.	pristane	24-56	lectin, galactose binding, soluble 3	Mus musculus	105-111
31601823-7	2019	In Lgals3+/+ pristane-induced mice, mesentery was hallmarked by intense fibrogranulomatous reaction restricted to submesothelial regions and organized niches containing macrophages and B lymphocytes and plasma cells.	pristane	13-21	lectin, galactose binding, soluble 3	Mus musculus	3-9
31601823-8	2019	In contrast, Lgals3-/- pristane-treated mice had diffuse mesenteric fibrosis affecting submesothelium and peripheral tissues, atypical M1/M2 macrophage polarization and significant DLL1+ cells expansion, suggesting possible involvement of Notch/Delta pathways in the disease.	pristane	23-31	lectin, galactose binding, soluble 3	Mus musculus	13-19
31601823-8	2019	In contrast, Lgals3-/- pristane-treated mice had diffuse mesenteric fibrosis affecting submesothelium and peripheral tissues, atypical M1/M2 macrophage polarization and significant DLL1+ cells expansion, suggesting possible involvement of Notch/Delta pathways in the disease.	pristane	23-31	delta like canonical Notch ligand 1	Mus musculus	181-185
31601823-9	2019	Early inflammatory reaction to pristane was characterized by significant disturbances on monocyte recruitment, macrophage differentiation and dendritic cell (DC) responses in the peritoneal cavity of pristane-induced Lgals3-/- mice.	pristane	31-39	lectin, galactose binding, soluble 3	Mus musculus	217-223
31601823-9	2019	Early inflammatory reaction to pristane was characterized by significant disturbances on monocyte recruitment, macrophage differentiation and dendritic cell (DC) responses in the peritoneal cavity of pristane-induced Lgals3-/- mice.	pristane	200-208	lectin, galactose binding, soluble 3	Mus musculus	217-223
31498792-12	2019	Downregulation of hippocampal NR2A subunit was more evident than NR2B in pristane and pristane+LPS at 7 and 12 weeks of treatment and it is related to learning and memory disturbance assayed by Barnes maze.	pristane	73-81	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	30-34
31498792-12	2019	Downregulation of hippocampal NR2A subunit was more evident than NR2B in pristane and pristane+LPS at 7 and 12 weeks of treatment and it is related to learning and memory disturbance assayed by Barnes maze.	pristane	73-81	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	65-69
31498792-12	2019	Downregulation of hippocampal NR2A subunit was more evident than NR2B in pristane and pristane+LPS at 7 and 12 weeks of treatment and it is related to learning and memory disturbance assayed by Barnes maze.	pristane	86-94	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	30-34
31498792-13	2019	This is the first report using the murine model of lupus induced by pristane that analyzes the NMDA subunit receptors, finding a downregulation of NR2A subunit related to learning and memory disturbance being more evident when they were exposed to LPS.	pristane	68-76	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	147-151
31470606-0	2019	Alpha-1-Antitrypsin Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice.	pristane	32-40	serpin family A member 1	Homo sapiens	0-19
33101313-8	2020	Pristane treatment significantly induced serum IFNalpha and expression of multiple interferon-stimulated genes (ISGs) in peripheral blood and peritoneal fluid cells, including inflammatory macrophages.	pristane	0-8	interferon alpha	Mus musculus	47-55
33101313-10	2020	Pristane induced comparable levels of inflammatory cells and cytokines in mice lacking the IFNalpha/beta receptor (IFNAR1-/-) or the IFNalpha/beta-inducing transcriptions factors (IRF3/7-/-), compared to WT mice.	pristane	0-8	interferon alpha	Mus musculus	91-104
33101313-10	2020	Pristane induced comparable levels of inflammatory cells and cytokines in mice lacking the IFNalpha/beta receptor (IFNAR1-/-) or the IFNalpha/beta-inducing transcriptions factors (IRF3/7-/-), compared to WT mice.	pristane	0-8	interferon regulatory factor 3	Mus musculus	180-186
33101313-11	2020	However, pristane-treated IFNAR1-/- and IRF3/7-/- mice failed to produce ISGs and produced significantly lower levels of transfusion-induced anti-KEL IgG, compared to WT mice.	pristane	9-17	interferon (alpha and beta) receptor 1	Mus musculus	26-32
33101313-11	2020	However, pristane-treated IFNAR1-/- and IRF3/7-/- mice failed to produce ISGs and produced significantly lower levels of transfusion-induced anti-KEL IgG, compared to WT mice.	pristane	9-17	interferon regulatory factor 3	Mus musculus	40-46
33101313-12	2020	Thus, pristane induction of a lupus-like phenotype promoted alloimmunization to the KEL RBC antigen in an IFNalpha/beta-dependent manner.	pristane	6-14	interferon alpha	Mus musculus	106-119
32503893-6	2020	Pkm2 intervention could alleviate the severity of pristane-induced arthritis in aspects of the macroscopic arthritis score, perimeter changes of midpaw, and the synovitis and destruction of the bone and cartilage as well as reduce the ED1 and p-Stat1-positive cell population in rat synovial tissues.	pristane	50-58	pyruvate kinase M1/2	Rattus norvegicus	0-4
32503893-6	2020	Pkm2 intervention could alleviate the severity of pristane-induced arthritis in aspects of the macroscopic arthritis score, perimeter changes of midpaw, and the synovitis and destruction of the bone and cartilage as well as reduce the ED1 and p-Stat1-positive cell population in rat synovial tissues.	pristane	50-58	signal transducer and activator of transcription 1	Rattus norvegicus	245-250
32487715-7	2020	In the pristane-induced lupus mouse model, inhibition of IRAK4 reduced the expression of IRGs during disease onset.	pristane	7-15	interleukin-1 receptor-associated kinase 4	Mus musculus	57-62
32487715-8	2020	Mice engineered to express kinase-deficient IRAK4 were protected from both chemical (pristane-induced) and genetic (NZB/W_F1 hybrid) models of lupus development.	pristane	85-93	interleukin-1 receptor-associated kinase 4	Mus musculus	44-49
32547538-9	2020	Importantly, Hspa13 mRNA was increased in B220+ cells from patients with multiple myeloma (MM) or SLE, whereas Hspa13 cKO led to reduced autoantibodies and proteinuria in both pristane-induced lupus and lupus-prone MRL/lpr mouse models.	pristane	176-184	heat shock protein family A (Hsp70) member 13	Homo sapiens	13-19
32547538-9	2020	Importantly, Hspa13 mRNA was increased in B220+ cells from patients with multiple myeloma (MM) or SLE, whereas Hspa13 cKO led to reduced autoantibodies and proteinuria in both pristane-induced lupus and lupus-prone MRL/lpr mouse models.	pristane	176-184	heat shock protein family A (Hsp70) member 13	Homo sapiens	111-117
31930775-2	2020	Pristane-induced SLE mice were treated with pyrrolidine dithiocarbamate (PDTC, 50 or 100 mg/kg), a NF-kappaB inhibitor.	pristane	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	99-108
31548308-3	2019	Here, we report that administration of the tumor-inducing agent pristane decreases Mtor gene expression to a greater extent in mesenteric lymph nodes of BALB/cAnPt mice than of DBA/2N mice.	pristane	64-72	mechanistic target of rapamycin kinase	Mus musculus	83-87
31548308-10	2019	Our results provide evidence that MZF1 down-regulates Mtor expression in pristane-induced plasmacytomas in mice.	pristane	73-81	myeloid zinc finger 1	Mus musculus	34-38
31548308-10	2019	Our results provide evidence that MZF1 down-regulates Mtor expression in pristane-induced plasmacytomas in mice.	pristane	73-81	mechanistic target of rapamycin kinase	Mus musculus	54-58
31311094-0	2019	NLRP3 Inflammasome Modulation by Melatonin Supplementation in Chronic Pristane-Induced Lupus Nephritis.	pristane	70-78	NLR family, pyrin domain containing 3	Mus musculus	0-5
31340848-0	2019	CD4+CD69+ T cells and CD4+CD25+FoxP3+ Treg cells imbalance in peripheral blood, spleen and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice.	pristane	114-122	CD4 antigen	Mus musculus	0-3
31340848-0	2019	CD4+CD69+ T cells and CD4+CD25+FoxP3+ Treg cells imbalance in peripheral blood, spleen and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice.	pristane	114-122	CD69 antigen	Mus musculus	4-8
31340848-0	2019	CD4+CD69+ T cells and CD4+CD25+FoxP3+ Treg cells imbalance in peripheral blood, spleen and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice.	pristane	114-122	CD4 antigen	Mus musculus	22-25
31340848-0	2019	CD4+CD69+ T cells and CD4+CD25+FoxP3+ Treg cells imbalance in peripheral blood, spleen and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice.	pristane	114-122	interleukin 2 receptor, alpha chain	Mus musculus	26-30
31340848-0	2019	CD4+CD69+ T cells and CD4+CD25+FoxP3+ Treg cells imbalance in peripheral blood, spleen and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice.	pristane	114-122	forkhead box P3	Mus musculus	31-36
31340848-13	2019	CONCLUSION: Increased numbers of CD4+CD69+ T cells and reduced numbers of CD4+CD25+FoxP3+ Treg cells with an altered interleukin profile suggests loss of autotolerance in pristane-induced lupus mice, which is similar to human lupus.	pristane	171-179	CD4 antigen	Mus musculus	74-77
31340848-13	2019	CONCLUSION: Increased numbers of CD4+CD69+ T cells and reduced numbers of CD4+CD25+FoxP3+ Treg cells with an altered interleukin profile suggests loss of autotolerance in pristane-induced lupus mice, which is similar to human lupus.	pristane	171-179	interleukin 2 receptor, alpha chain	Mus musculus	78-82
31340848-13	2019	CONCLUSION: Increased numbers of CD4+CD69+ T cells and reduced numbers of CD4+CD25+FoxP3+ Treg cells with an altered interleukin profile suggests loss of autotolerance in pristane-induced lupus mice, which is similar to human lupus.	pristane	171-179	forkhead box P3	Mus musculus	83-88
31262710-9	2019	Furthermore, SMS1 knockout mice showed reduced production and deposition of autoantibodies, accompanied by less severe kidney pathological changes after pristane induction.	pristane	153-161	sphingomyelin synthase 1	Mus musculus	13-17
31023362-0	2019	Baicalein ameliorates pristane-induced lupus nephritis via activating Nrf2/HO-1 in myeloid-derived suppressor cells.	pristane	22-30	nuclear factor, erythroid derived 2, like 2	Mus musculus	70-74
31311094-7	2019	Our results showed that melatonin attenuates pristane-induced LN through restoring of morphology and attenuation of oxidative stress and inflammation through a pathway that inhibited activation of NLRP3 inflammasome signaling.	pristane	45-53	NLR family, pyrin domain containing 3	Mus musculus	197-202
31023362-0	2019	Baicalein ameliorates pristane-induced lupus nephritis via activating Nrf2/HO-1 in myeloid-derived suppressor cells.	pristane	22-30	heme oxygenase 1	Mus musculus	75-79
31023362-15	2019	CONCLUSION: The data show that baicalein alleviates the symptoms of pristane-induced LN and suggest that the alleviation may be attributed to inhibition of MDSC expansion and regulation of the balance of the Nrf2/HO-1 signal and NLRP3 expression in MDSCs.	pristane	68-76	nuclear factor, erythroid derived 2, like 2	Mus musculus	208-212
31023362-15	2019	CONCLUSION: The data show that baicalein alleviates the symptoms of pristane-induced LN and suggest that the alleviation may be attributed to inhibition of MDSC expansion and regulation of the balance of the Nrf2/HO-1 signal and NLRP3 expression in MDSCs.	pristane	68-76	heme oxygenase 1	Mus musculus	213-217
31023362-15	2019	CONCLUSION: The data show that baicalein alleviates the symptoms of pristane-induced LN and suggest that the alleviation may be attributed to inhibition of MDSC expansion and regulation of the balance of the Nrf2/HO-1 signal and NLRP3 expression in MDSCs.	pristane	68-76	NLR family, pyrin domain containing 3	Mus musculus	229-234
31105830-3	2019	The present study was undertaken to establish the link between miR-147 and TLR-7 in rat macrophages (in vitro) and in pristane (PS) induced arthritic rats.	pristane	118-126	microRNA 147	Rattus norvegicus	63-70
31013255-6	2019	EPO/EPO-R ligations on CD4+ T cells abrogate, while absence of T cell-expressed EPO-R augments, TH17 induction and clinical/histological expression of pristane-induced glomerulonephritis (associated with decreased intrarenal EPO).	pristane	151-159	erythropoietin	Mus musculus	0-3
31013255-6	2019	EPO/EPO-R ligations on CD4+ T cells abrogate, while absence of T cell-expressed EPO-R augments, TH17 induction and clinical/histological expression of pristane-induced glomerulonephritis (associated with decreased intrarenal EPO).	pristane	151-159	erythropoietin receptor	Mus musculus	4-9
31013255-6	2019	EPO/EPO-R ligations on CD4+ T cells abrogate, while absence of T cell-expressed EPO-R augments, TH17 induction and clinical/histological expression of pristane-induced glomerulonephritis (associated with decreased intrarenal EPO).	pristane	151-159	erythropoietin receptor	Mus musculus	80-85
31013255-6	2019	EPO/EPO-R ligations on CD4+ T cells abrogate, while absence of T cell-expressed EPO-R augments, TH17 induction and clinical/histological expression of pristane-induced glomerulonephritis (associated with decreased intrarenal EPO).	pristane	151-159	erythropoietin	Mus musculus	4-7
30840833-9	2019	Moreover, although absence of SphK2 increased pDC frequency in pristane-induced lupus, there were no major changes in their activation status.	pristane	63-71	sphingosine kinase 2	Mus musculus	30-35
30840833-9	2019	Moreover, although absence of SphK2 increased pDC frequency in pristane-induced lupus, there were no major changes in their activation status.	pristane	63-71	phosducin	Mus musculus	46-49
30753473-1	2019	Toll-like receptor 7 (TLR7) and type I interferons (IFN-1) are essential for the development of systemic lupus erythematosus (SLE) models such as BXSB.Yaa and 2,6,10,14-tetramethyl-pentadecane (TMPD)-induced experimental lupus.	pristane	159-192	toll-like receptor 7	Mus musculus	0-20
30753473-1	2019	Toll-like receptor 7 (TLR7) and type I interferons (IFN-1) are essential for the development of systemic lupus erythematosus (SLE) models such as BXSB.Yaa and 2,6,10,14-tetramethyl-pentadecane (TMPD)-induced experimental lupus.	pristane	159-192	toll-like receptor 7	Mus musculus	22-26
30753473-1	2019	Toll-like receptor 7 (TLR7) and type I interferons (IFN-1) are essential for the development of systemic lupus erythematosus (SLE) models such as BXSB.Yaa and 2,6,10,14-tetramethyl-pentadecane (TMPD)-induced experimental lupus.	pristane	194-198	toll-like receptor 7	Mus musculus	0-20
30753473-1	2019	Toll-like receptor 7 (TLR7) and type I interferons (IFN-1) are essential for the development of systemic lupus erythematosus (SLE) models such as BXSB.Yaa and 2,6,10,14-tetramethyl-pentadecane (TMPD)-induced experimental lupus.	pristane	194-198	toll-like receptor 7	Mus musculus	22-26
31105830-3	2019	The present study was undertaken to establish the link between miR-147 and TLR-7 in rat macrophages (in vitro) and in pristane (PS) induced arthritic rats.	pristane	118-126	toll-like receptor 7	Rattus norvegicus	75-80
30257456-1	2018	Previous work from our group has shown that Cd38-/- mice develop a milder pristane-induced lupus disease than WT or Art2-/- counterparts, demonstrating a new role for CD38 in promoting aberrant inflammation and lupus-like autoimmunity via a Transient Receptor Potential Melastatin 2 (TRPM2)-dependent apoptosis-driven mechanism.	pristane	74-82	CD38 antigen	Mus musculus	44-48
30275535-3	2018	In the present study, we identified that FBXW7 is a crucial exacerbating factor for SLE development and progression in a mouse model induced by 2, 6, 10, 14-tetramethylpentadecane (TMPD).	pristane	144-179	F-box and WD-40 domain protein 7	Mus musculus	41-46
30316188-9	2018	If miR-199a antagomir was administrated after 48 h of pristane administration, the expression of p-P65 and the secretion of TNF-alpha and IL-1beta were significantly down-regulated in LN kidney.	pristane	54-62	tumor necrosis factor	Homo sapiens	124-133
30316188-9	2018	If miR-199a antagomir was administrated after 48 h of pristane administration, the expression of p-P65 and the secretion of TNF-alpha and IL-1beta were significantly down-regulated in LN kidney.	pristane	54-62	interleukin 1 beta	Homo sapiens	138-146
30049830-8	2018	RESULTS: DNA sequencing and subcongenic strains studied in pristane-induced arthritis identified a new amino acid changing functional variant in HIP1.	pristane	59-67	huntingtin interacting protein 1	Rattus norvegicus	145-149
30257884-5	2018	SLE phenotypes were effectively alleviated in Wdfy4-CKO mice, with significantly diminished pristane-elicited production of autoantibodies and glomerulonephritis.	pristane	92-100	WD repeat and FYVE domain containing 4	Mus musculus	46-51
30257456-3	2018	In pristane-treated mice the frequency of spleen CD19+CD1dhiCD5+ B cells, which are highly enriched in B10 cells, was significantly increased in Cd38-/- splenocytes compared to WT, while the frequency of peritoneal plasmacytoid dendritic cells (pDCs), which are major type I Interferon (IFN) producers, was greatly diminished.	pristane	3-11	CD19 antigen	Mus musculus	49-53
30257456-3	2018	In pristane-treated mice the frequency of spleen CD19+CD1dhiCD5+ B cells, which are highly enriched in B10 cells, was significantly increased in Cd38-/- splenocytes compared to WT, while the frequency of peritoneal plasmacytoid dendritic cells (pDCs), which are major type I Interferon (IFN) producers, was greatly diminished.	pristane	3-11	CD38 antigen	Mus musculus	145-149
30089723-0	2018	IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation.	pristane	55-63	interleukin 16	Homo sapiens	0-5
29992753-4	2018	In rats with pristane-induced arthritis (PIA), TLR9 inhibition before disease onset reduced arthritis significantly and almost completely abolished bone erosion.	pristane	13-21	toll-like receptor 9	Rattus norvegicus	47-51
30089723-0	2018	IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation.	pristane	55-63	microRNA 125a	Homo sapiens	6-14
30089723-4	2018	Furthermore, in the pristane model of acute "SLE-like" lung inflammation and alveolar hemorrhage, we observed reduced pulmonary miR-125a and enhanced IL-16 expression.	pristane	20-28	microRNA 125a	Homo sapiens	128-136
30089723-4	2018	Furthermore, in the pristane model of acute "SLE-like" lung inflammation and alveolar hemorrhage, we observed reduced pulmonary miR-125a and enhanced IL-16 expression.	pristane	20-28	interleukin 16	Homo sapiens	150-155
30089723-5	2018	Neutrophil infiltration was markedly reduced in the peritoneal lavage of pristane-treated IL-16-deficient mice and elevated following i.n.	pristane	73-81	interleukin 16	Mus musculus	90-95
30089723-7	2018	Moreover, a miR-125a mimic reduced pristane-induced IL-16 expression and neutrophil recruitment and rescued lung pathology.	pristane	35-43	microRNA 125a	Homo sapiens	12-20
30089723-7	2018	Moreover, a miR-125a mimic reduced pristane-induced IL-16 expression and neutrophil recruitment and rescued lung pathology.	pristane	35-43	interleukin 16	Homo sapiens	52-57
29879320-0	2018	Effect of active immunization with IL-17A on B cell function and infection risk in pristane-induced lupus model.	pristane	83-91	interleukin 17A	Mus musculus	35-41
29879320-11	2018	CONCLUSION: Active immunization with IL-17A coupled to KLH was able to induce a high titer of neutralizing antibodies against IL-17A and inhibit B cell functions without increasing the risk of infection in a pristane-induced lupus mice model.	pristane	208-216	interleukin 17A	Mus musculus	37-43
29879320-11	2018	CONCLUSION: Active immunization with IL-17A coupled to KLH was able to induce a high titer of neutralizing antibodies against IL-17A and inhibit B cell functions without increasing the risk of infection in a pristane-induced lupus mice model.	pristane	208-216	interleukin 17A	Mus musculus	126-132
28669029-0	2017	Slc11a1 (Nramp-1) gene modulates immune-inflammation genes in macrophages during pristane-induced arthritis in mice.	pristane	81-89	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	Mus musculus	0-7
29483158-5	2018	In mouse models of crescentic GN (nephrotoxic nephritis) and pristane-induced lupus nephritis, deficiency in IL-17C significantly ameliorated the course of GN in terms of renal tissue injury and kidney function.	pristane	61-69	interleukin 17C	Mus musculus	109-115
29480020-7	2018	Treatment with quercetin in the pristane-induced LN mice model was nephroprotective, decreasing proteinuria levels and significantly lowering tissue expression of IL-6, TNF-alpha, TGF-beta1, Bax and TBARS.	pristane	32-40	interleukin 6	Mus musculus	163-167
29480020-7	2018	Treatment with quercetin in the pristane-induced LN mice model was nephroprotective, decreasing proteinuria levels and significantly lowering tissue expression of IL-6, TNF-alpha, TGF-beta1, Bax and TBARS.	pristane	32-40	tumor necrosis factor	Mus musculus	169-178
29480020-7	2018	Treatment with quercetin in the pristane-induced LN mice model was nephroprotective, decreasing proteinuria levels and significantly lowering tissue expression of IL-6, TNF-alpha, TGF-beta1, Bax and TBARS.	pristane	32-40	transforming growth factor, beta 1	Mus musculus	180-189
29480020-7	2018	Treatment with quercetin in the pristane-induced LN mice model was nephroprotective, decreasing proteinuria levels and significantly lowering tissue expression of IL-6, TNF-alpha, TGF-beta1, Bax and TBARS.	pristane	32-40	BCL2-associated X protein	Mus musculus	191-194
29463868-0	2018	CD38 promotes pristane-induced chronic inflammation and increases susceptibility to experimental lupus by an apoptosis-driven and TRPM2-dependent mechanism.	pristane	14-22	CD38 antigen	Mus musculus	0-4
29463868-3	2018	Cd38-/- pristane-elicited peritoneal exudate cells had defective CCL2 and TNF-alpha secretion following TLR7 stimulation.	pristane	8-16	CD38 antigen	Mus musculus	0-4
29463868-3	2018	Cd38-/- pristane-elicited peritoneal exudate cells had defective CCL2 and TNF-alpha secretion following TLR7 stimulation.	pristane	8-16	chemokine (C-C motif) ligand 2	Mus musculus	65-69
29463868-3	2018	Cd38-/- pristane-elicited peritoneal exudate cells had defective CCL2 and TNF-alpha secretion following TLR7 stimulation.	pristane	8-16	tumor necrosis factor	Mus musculus	74-83
29463868-3	2018	Cd38-/- pristane-elicited peritoneal exudate cells had defective CCL2 and TNF-alpha secretion following TLR7 stimulation.	pristane	8-16	toll-like receptor 7	Mus musculus	104-108
29463868-9	2018	Furthermore, given the implications of CD38 in the activation of TRPM2, our data suggest that CD38 modulation of pristane-induced apoptosis is TRPM2-dependent.	pristane	113-121	CD38 antigen	Mus musculus	39-43
29463868-9	2018	Furthermore, given the implications of CD38 in the activation of TRPM2, our data suggest that CD38 modulation of pristane-induced apoptosis is TRPM2-dependent.	pristane	113-121	transient receptor potential cation channel, subfamily M, member 2	Mus musculus	65-70
29463868-9	2018	Furthermore, given the implications of CD38 in the activation of TRPM2, our data suggest that CD38 modulation of pristane-induced apoptosis is TRPM2-dependent.	pristane	113-121	CD38 antigen	Mus musculus	94-98
29463868-9	2018	Furthermore, given the implications of CD38 in the activation of TRPM2, our data suggest that CD38 modulation of pristane-induced apoptosis is TRPM2-dependent.	pristane	113-121	transient receptor potential cation channel, subfamily M, member 2	Mus musculus	143-148
29422534-3	2018	Conditional deletion of Rfx1 in mice exacerbates experimental autoimmune encephalomyelitis and pristane-induced lupus-like syndrome and increases induction of Th17 cells.	pristane	95-103	regulatory factor X, 1 (influences HLA class II expression)	Mus musculus	24-28
29456535-5	2018	Peritoneal macrophages from pristane-treated mice had an M1 phenotype, high HIFalpha-regulated phosphofructokinase and TNFalpha expression (quantitative PCR, flow cytometry), and low expression of the LXRalpha-regulated gene ATP binding cassette subfamily A member 1 (Abca1) and Il10 vs. mice treated with mineral oil, a control inflammatory oil that does not cause lupus.	pristane	28-36	tumor necrosis factor	Mus musculus	119-127
29456535-5	2018	Peritoneal macrophages from pristane-treated mice had an M1 phenotype, high HIFalpha-regulated phosphofructokinase and TNFalpha expression (quantitative PCR, flow cytometry), and low expression of the LXRalpha-regulated gene ATP binding cassette subfamily A member 1 (Abca1) and Il10 vs. mice treated with mineral oil, a control inflammatory oil that does not cause lupus.	pristane	28-36	nuclear receptor subfamily 1, group H, member 3	Mus musculus	201-209
29456535-5	2018	Peritoneal macrophages from pristane-treated mice had an M1 phenotype, high HIFalpha-regulated phosphofructokinase and TNFalpha expression (quantitative PCR, flow cytometry), and low expression of the LXRalpha-regulated gene ATP binding cassette subfamily A member 1 (Abca1) and Il10 vs. mice treated with mineral oil, a control inflammatory oil that does not cause lupus.	pristane	28-36	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	225-266
29456535-5	2018	Peritoneal macrophages from pristane-treated mice had an M1 phenotype, high HIFalpha-regulated phosphofructokinase and TNFalpha expression (quantitative PCR, flow cytometry), and low expression of the LXRalpha-regulated gene ATP binding cassette subfamily A member 1 (Abca1) and Il10 vs. mice treated with mineral oil, a control inflammatory oil that does not cause lupus.	pristane	28-36	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	268-273
29456535-5	2018	Peritoneal macrophages from pristane-treated mice had an M1 phenotype, high HIFalpha-regulated phosphofructokinase and TNFalpha expression (quantitative PCR, flow cytometry), and low expression of the LXRalpha-regulated gene ATP binding cassette subfamily A member 1 (Abca1) and Il10 vs. mice treated with mineral oil, a control inflammatory oil that does not cause lupus.	pristane	28-36	interleukin 10	Mus musculus	279-283
29456535-6	2018	Glycolytic metabolism (extracellular flux assays) and Hif1a expression were higher in pristane-treated mice (M1-like) whereas oxidative metabolism and LXRalpha expression were higher in mineral oil-treated mice (M2-like).	pristane	86-94	hypoxia inducible factor 1, alpha subunit	Mus musculus	54-59
29618665-5	2018	In contrast, B cell-specific deletion of GARP-encoding gene Lrrc32 in mice led to development of systemic autoimmune diseases spontaneously as well as worsening of pristane-induced lupus-like disease.	pristane	164-172	leucine rich repeat containing 32	Mus musculus	41-45
29618665-5	2018	In contrast, B cell-specific deletion of GARP-encoding gene Lrrc32 in mice led to development of systemic autoimmune diseases spontaneously as well as worsening of pristane-induced lupus-like disease.	pristane	164-172	leucine rich repeat containing 32	Mus musculus	60-66
29182672-0	2017	Increased expression of Th17 cytokines and interleukin-22 correlates with disease activity in pristane-induced arthritis in rats.	pristane	94-102	interleukin 22	Rattus norvegicus	43-57
28669029-0	2017	Slc11a1 (Nramp-1) gene modulates immune-inflammation genes in macrophages during pristane-induced arthritis in mice.	pristane	81-89	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	Mus musculus	9-16
28696256-7	2017	The peritoneal exudate of pristane-treated mice contained mainly Ly6Chi inflammatory monocytes; whereas in MO-treated mice, it consisted predominantly of a novel subset of highly phagocytic MPhi resembling small peritoneal MPhi (SPM) that expressed CD138+ and the scavenger receptor Marco.	pristane	26-34	syndecan 1	Mus musculus	249-254
28719617-1	2017	OBJECTIVE: We herein examine the role of endogenous miR155 in the development of systemic manifestations in pristane induced lupus.	pristane	108-116	microRNA 155	Mus musculus	52-58
28627588-0	2017	IL-22 expression is increased variedly in the initial phase, onset and chronic phase of a pristane-induced arthritis rat model.	pristane	90-98	interleukin 22	Rattus norvegicus	0-5
28719617-2	2017	MATERIALS AND METHODS: Systemic lupus in miR155-deficient and wild type mice was induced upon injection of pristane and analyzed after 8 months, PBS-injected mice served as controls.	pristane	107-115	microRNA 155	Mus musculus	41-47
28199309-8	2017	PI3Kdelta inhibitors or ibrutinib increased the formation of AID-dependent tumours in pristane-treated mice.	pristane	86-94	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Mus musculus	0-9
28719617-10	2017	Pristane-treated wild types showed significantly up-regulated expression of genes related to the INF-signature (MX1, IP10, IRF7, ISG15).	pristane	0-8	MX dynamin-like GTPase 1	Mus musculus	112-115
28719617-10	2017	Pristane-treated wild types showed significantly up-regulated expression of genes related to the INF-signature (MX1, IP10, IRF7, ISG15).	pristane	0-8	chemokine (C-X-C motif) ligand 10	Mus musculus	117-121
28719617-10	2017	Pristane-treated wild types showed significantly up-regulated expression of genes related to the INF-signature (MX1, IP10, IRF7, ISG15).	pristane	0-8	interferon regulatory factor 7	Mus musculus	123-127
28719617-10	2017	Pristane-treated wild types showed significantly up-regulated expression of genes related to the INF-signature (MX1, IP10, IRF7, ISG15).	pristane	0-8	ISG15 ubiquitin-like modifier	Mus musculus	129-134
28217966-11	2017	Mortality was increased in interleukin-10 (IL-10)-deficient mice, and pristane treatment decreased IL-10 receptor expression in monocytes and STAT-3 phosphorylation in lung macrophages.	pristane	70-78	interleukin 10	Mus musculus	99-104
28217966-11	2017	Mortality was increased in interleukin-10 (IL-10)-deficient mice, and pristane treatment decreased IL-10 receptor expression in monocytes and STAT-3 phosphorylation in lung macrophages.	pristane	70-78	signal transducer and activator of transcription 3	Mus musculus	142-148
28515366-4	2017	Pristane-induced lupus (PIL) was aggravated in 2 mouse strains with impaired induction of NET formation, i.e., NOX2-deficient (Ncf1-mutated) and peptidyl arginine deiminase 4-deficient (PAD4-deficient) mice, as seen from elevated levels of antinuclear autoantibodies (ANAs) and exacerbated glomerulonephritis.	pristane	0-8	ELK3, member of ETS oncogene family	Mus musculus	90-93
28515366-4	2017	Pristane-induced lupus (PIL) was aggravated in 2 mouse strains with impaired induction of NET formation, i.e., NOX2-deficient (Ncf1-mutated) and peptidyl arginine deiminase 4-deficient (PAD4-deficient) mice, as seen from elevated levels of antinuclear autoantibodies (ANAs) and exacerbated glomerulonephritis.	pristane	0-8	neutrophil cytosolic factor 1	Mus musculus	127-131
28515366-5	2017	We observed a dramatically reduced ability to form pristane-induced NETs in vivo in both Ncf1-mutated and PAD4-deficient mice, accompanied by higher levels of inflammatory mediators in the peritoneum.	pristane	51-59	neutrophil cytosolic factor 1	Mus musculus	89-93
28303221-0	2017	Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice.	pristane	86-94	serum amyloid A cluster	Mus musculus	0-18
28303221-1	2017	The purpose of this study was to investigate the effects of salvianolic acid A (SAA) in systemic lupus erythematosus (SLE) induced by pristane in BALB/c mice.	pristane	134-142	serum amyloid A cluster	Mus musculus	80-83
28303221-8	2017	In conclusion, the results suggest that SAA alleviates renal injury in pristane-induced SLE in BALB/c mice through inhibition of phosphorylation of IKK, IkappaB and NFkappaB.	pristane	71-79	serum amyloid A cluster	Mus musculus	40-43
28303221-8	2017	In conclusion, the results suggest that SAA alleviates renal injury in pristane-induced SLE in BALB/c mice through inhibition of phosphorylation of IKK, IkappaB and NFkappaB.	pristane	71-79	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	165-173
28300427-0	2017	Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.	pristane	43-51	annexin A1	Mus musculus	0-10
28300427-9	2017	In the present study, we investigated the possibility to modulate the autoimmune response in a pristane-induced mouse model of SLE using an anti- ANX A1 antibody.	pristane	95-103	annexin A1	Mus musculus	146-152
28318807-4	2017	In vivo evaluation revealed that miR-302d protects against pristane-induced inflammation in mice by targeting IRF9 and hence ISG expression.	pristane	59-67	microRNA 302d	Mus musculus	33-41
28318807-4	2017	In vivo evaluation revealed that miR-302d protects against pristane-induced inflammation in mice by targeting IRF9 and hence ISG expression.	pristane	59-67	interferon regulatory factor 9	Mus musculus	110-114
28183532-3	2017	Here, we identified the growth factor midkine (MK; gene name, Mdk) as a novel regulator in the pathogenesis of 2,6,10,14-tetramethylpentadecane-induced LN via activation of NFAT and IL-12/STAT4 signaling.	pristane	111-143	midkine	Mus musculus	62-65
28183532-3	2017	Here, we identified the growth factor midkine (MK; gene name, Mdk) as a novel regulator in the pathogenesis of 2,6,10,14-tetramethylpentadecane-induced LN via activation of NFAT and IL-12/STAT4 signaling.	pristane	111-143	signal transducer and activator of transcription 4	Mus musculus	188-193
27768123-2	2017	In this study, we explore the effect of milk fat globule-EGF factor 8 (MFG-E8) on the aberrant nitrification features in pristane-induced lupus.	pristane	121-129	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	40-69
27768123-2	2017	In this study, we explore the effect of milk fat globule-EGF factor 8 (MFG-E8) on the aberrant nitrification features in pristane-induced lupus.	pristane	121-129	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	71-77
27768123-3	2017	SLE patients and mice with pristane-induced lupus develop autoantibodies associated with MFG-E8 overproduction.	pristane	27-35	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	89-95
27768123-4	2017	However, the deletion of MFG-E8 leads to uncontrolled early pulmonary and peritoneal inflammation and tissue damage in mice with pristane-induced lupus.	pristane	129-137	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	25-31
27768123-5	2017	Consistent with these findings, MFG-E8-deficient mice that are exposed to pristane show enhanced neutrophil accumulation and increased neutrophil death, including apoptosis, necrosis and NETosis, as well as impaired phagocytosis of macrophages.	pristane	74-82	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	32-38
27768123-7	2017	In patients with SLE and mice with pristane-induced lupus, neutrophil accumulation is elevated, which depends on higher expression of the surface receptor CXCR2.	pristane	35-43	chemokine (C-X-C motif) receptor 2	Mus musculus	155-160
27274010-7	2016	RESULTS: Wild-type C57BL/6 mice with pristane-induced lupus developed a strong IFN signature, which was absent in immunoglobulin-deficient (muMT), C3-/- , and CD18-/- mice.	pristane	37-45	interferon alpha 1	Homo sapiens	79-82
27940139-0	2017	Pristane induces autophagy in macrophages, promoting a STAT1-IRF1-TLR3 pathway and arthritis.	pristane	0-8	signal transducer and activator of transcription 1	Rattus norvegicus	55-60
27940139-0	2017	Pristane induces autophagy in macrophages, promoting a STAT1-IRF1-TLR3 pathway and arthritis.	pristane	0-8	interferon regulatory factor 1	Rattus norvegicus	61-65
27940139-0	2017	Pristane induces autophagy in macrophages, promoting a STAT1-IRF1-TLR3 pathway and arthritis.	pristane	0-8	toll-like receptor 3	Rattus norvegicus	66-70
27940139-2	2017	We propose that autophagy regulates activation of TLR3 in macrophages and is thereby essential for development of pristane-induced arthritis.	pristane	114-122	toll-like receptor 3	Rattus norvegicus	50-54
27940139-5	2017	Blocking the pristane activated autophagy by Wortmannin and Bafilomycin A1 or by RNAi of Becn1 led to a downregulation of the associated STAT1-IRF1-TLR3 pathway.	pristane	13-21	beclin 1	Rattus norvegicus	89-94
27940139-5	2017	Blocking the pristane activated autophagy by Wortmannin and Bafilomycin A1 or by RNAi of Becn1 led to a downregulation of the associated STAT1-IRF1-TLR3 pathway.	pristane	13-21	signal transducer and activator of transcription 1	Rattus norvegicus	137-142
27940139-5	2017	Blocking the pristane activated autophagy by Wortmannin and Bafilomycin A1 or by RNAi of Becn1 led to a downregulation of the associated STAT1-IRF1-TLR3 pathway.	pristane	13-21	interferon regulatory factor 1	Rattus norvegicus	143-147
27940139-5	2017	Blocking the pristane activated autophagy by Wortmannin and Bafilomycin A1 or by RNAi of Becn1 led to a downregulation of the associated STAT1-IRF1-TLR3 pathway.	pristane	13-21	toll-like receptor 3	Rattus norvegicus	148-152
27940139-7	2017	We conclude that pristane enhanced autophagy, leading to a STAT1-IRF1 controlled upregulation of TLR3 expression in macrophages, is a pathogenic mechanism in the development of arthritis.	pristane	17-25	signal transducer and activator of transcription 1	Rattus norvegicus	59-64
27940139-7	2017	We conclude that pristane enhanced autophagy, leading to a STAT1-IRF1 controlled upregulation of TLR3 expression in macrophages, is a pathogenic mechanism in the development of arthritis.	pristane	17-25	interferon regulatory factor 1	Rattus norvegicus	65-69
27940139-7	2017	We conclude that pristane enhanced autophagy, leading to a STAT1-IRF1 controlled upregulation of TLR3 expression in macrophages, is a pathogenic mechanism in the development of arthritis.	pristane	17-25	toll-like receptor 3	Rattus norvegicus	97-101
28039299-7	2017	Nlrp3-R258W mutant mice exhibited significantly higher mortality upon pristane challenge.	pristane	70-78	NLR family, pyrin domain containing 3	Mus musculus	0-5
29201923-5	2017	We found that the loss of IL-6 decreased macrophage recruitment to the spleen and the peritoneal cavity during pristane-induced inflammation.	pristane	111-119	interleukin 6	Mus musculus	26-30
27274010-7	2016	RESULTS: Wild-type C57BL/6 mice with pristane-induced lupus developed a strong IFN signature, which was absent in immunoglobulin-deficient (muMT), C3-/- , and CD18-/- mice.	pristane	37-45	integrin beta 2	Mus musculus	159-163
26773156-0	2016	C1q Modulates the Response to TLR7 Stimulation by Pristane-Primed Macrophages: Implications for Pristane-Induced Lupus.	pristane	50-58	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	0-3
27354219-8	2016	TMPD-injected Tlr9(-/-) BALB/c mice develop higher autoantibody titers against RNA, neutrophil cytoplasmic Ags, and myeloperoxidase than do TMPD-injected wild-type BALB/c mice.	pristane	0-4	toll-like receptor 9	Mus musculus	14-18
27354219-8	2016	TMPD-injected Tlr9(-/-) BALB/c mice develop higher autoantibody titers against RNA, neutrophil cytoplasmic Ags, and myeloperoxidase than do TMPD-injected wild-type BALB/c mice.	pristane	0-4	myeloperoxidase	Mus musculus	116-131
27354219-11	2016	Therefore, the BALB/c pristane model recapitulates other TLR7-driven spontaneous models of SLE and is negatively regulated by TLR9.	pristane	22-30	toll-like receptor 7	Mus musculus	57-61
27354219-11	2016	Therefore, the BALB/c pristane model recapitulates other TLR7-driven spontaneous models of SLE and is negatively regulated by TLR9.	pristane	22-30	toll-like receptor 9	Mus musculus	126-130
26657791-0	2016	Immunosuppressive CD11b+Ly6Chi monocytes in pristane-induced lupus mouse model.	pristane	44-52	integrin alpha M	Mus musculus	18-23
26657791-3	2016	In the current study, when we attempted to characterize the peritoneal cells in pristane-induced lupus model, as reported previously, we observed that there were markedly increased CD11b(+)Ly6C(hi) monocytes.	pristane	80-88	integrin alpha M	Mus musculus	181-186
26657791-7	2016	Consistent with the in vitro experimental results, the in vivo adoptive cell transfer study showed that infusion of pristane-treated syngeneic CD11b(+)Ly6C(hi) monocytes significantly suppressed the production of anti-keyhole limpet hemocyanin antibodies induced by keyhole limpet hemocyanin immunization.	pristane	116-124	integrin alpha M	Mus musculus	143-148
26657791-9	2016	Our findings indicate that CD11b(+)Ly6C(hi) monocytes in a pristane-induced lupus mouse model are monocytic myeloid-derived suppressor cells instead of inflammatory monocytes, as demonstrated previously.	pristane	59-67	integrin alpha M	Mus musculus	27-32
26657791-10	2016	To our knowledge, this is the first to describe myeloid-derived suppressor cells in a pristane-induced lupus mouse model, which may lead to a better understanding of the role of CD11b(+)Ly6C(hi) monocytes in this specific pristane-induced lupus model.	pristane	86-94	integrin alpha M	Mus musculus	178-183
26821304-4	2016	In the pristane-induced DBA/1 lupus model, Btk inhibition suppressed arthritis, but autoantibodies and the IFN gene signature were not significantly affected; suggesting efficacy was mediated through inhibition of Fc receptors.	pristane	7-15	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	43-46
27760209-4	2016	At week 14, the pristane-SNF1 model recapitulated kidney disease parameters and molecular signatures seen in spontaneous disease in 36 week-old SNF1 mice and in a traditional IFNalpha-accelerated NZB X NZW F1 (BWF1) model.	pristane	16-24	WD repeat and FYVE domain containing 3	Mus musculus	210-214
27125291-9	2016	IL-17, TNF-alpha, and BAFF levels were significantly higher in pristane-injected BALB/c mice than BALB/c mice and pristane-injected HBV(Tg) mice.	pristane	63-71	interleukin 17A	Mus musculus	0-5
27125291-9	2016	IL-17, TNF-alpha, and BAFF levels were significantly higher in pristane-injected BALB/c mice than BALB/c mice and pristane-injected HBV(Tg) mice.	pristane	63-71	tumor necrosis factor	Mus musculus	7-16
27125291-9	2016	IL-17, TNF-alpha, and BAFF levels were significantly higher in pristane-injected BALB/c mice than BALB/c mice and pristane-injected HBV(Tg) mice.	pristane	63-71	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	22-26
27125291-10	2016	IL-2, IL-4, and IL-6 levels were much higher in pristane-injected HBV(Tg) mice than pristane-injected BALB/c mice.	pristane	48-56	interleukin 2	Mus musculus	0-4
27125291-10	2016	IL-2, IL-4, and IL-6 levels were much higher in pristane-injected HBV(Tg) mice than pristane-injected BALB/c mice.	pristane	48-56	interleukin 4	Mus musculus	6-10
27125291-10	2016	IL-2, IL-4, and IL-6 levels were much higher in pristane-injected HBV(Tg) mice than pristane-injected BALB/c mice.	pristane	48-56	interleukin 6	Mus musculus	16-20
27385322-9	2016	CONCLUSIONS: We concluded that pristane treated apoE-/- mice exhibited lupus-like phenotype and developed atherosclerosis.	pristane	31-39	apolipoprotein E	Mus musculus	48-52
27385322-10	2016	The pristane treatment also induced abnormally high expression of TLR2 and TLR4 in the aorta and TLR2, TLR4, TLR7 and TLR9 in the kidney of apoE-/- mice.	pristane	4-12	toll-like receptor 2	Mus musculus	66-70
27385322-10	2016	The pristane treatment also induced abnormally high expression of TLR2 and TLR4 in the aorta and TLR2, TLR4, TLR7 and TLR9 in the kidney of apoE-/- mice.	pristane	4-12	toll-like receptor 4	Mus musculus	75-79
27385322-10	2016	The pristane treatment also induced abnormally high expression of TLR2 and TLR4 in the aorta and TLR2, TLR4, TLR7 and TLR9 in the kidney of apoE-/- mice.	pristane	4-12	toll-like receptor 2	Mus musculus	97-101
27385322-10	2016	The pristane treatment also induced abnormally high expression of TLR2 and TLR4 in the aorta and TLR2, TLR4, TLR7 and TLR9 in the kidney of apoE-/- mice.	pristane	4-12	toll-like receptor 4	Mus musculus	103-107
27385322-10	2016	The pristane treatment also induced abnormally high expression of TLR2 and TLR4 in the aorta and TLR2, TLR4, TLR7 and TLR9 in the kidney of apoE-/- mice.	pristane	4-12	toll-like receptor 7	Mus musculus	109-113
27385322-10	2016	The pristane treatment also induced abnormally high expression of TLR2 and TLR4 in the aorta and TLR2, TLR4, TLR7 and TLR9 in the kidney of apoE-/- mice.	pristane	4-12	toll-like receptor 9	Mus musculus	118-122
27385322-10	2016	The pristane treatment also induced abnormally high expression of TLR2 and TLR4 in the aorta and TLR2, TLR4, TLR7 and TLR9 in the kidney of apoE-/- mice.	pristane	4-12	apolipoprotein E	Mus musculus	140-144
27357136-7	2016	Pristane-treated WT mice showed elevated anti-dsDNA, anti-snRNP, CXCL1, and MCP-1 levels compared to untreated mice; however levels of anti-snRNP, MCP-1, and CXCL1 were reduced in pristane-treated Psgl-1(-/-) mice compared to pristane-treated WT mice.	pristane	0-8	LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated	Mus musculus	58-63
27357136-7	2016	Pristane-treated WT mice showed elevated anti-dsDNA, anti-snRNP, CXCL1, and MCP-1 levels compared to untreated mice; however levels of anti-snRNP, MCP-1, and CXCL1 were reduced in pristane-treated Psgl-1(-/-) mice compared to pristane-treated WT mice.	pristane	0-8	chemokine (C-X-C motif) ligand 1	Mus musculus	65-70
27357136-7	2016	Pristane-treated WT mice showed elevated anti-dsDNA, anti-snRNP, CXCL1, and MCP-1 levels compared to untreated mice; however levels of anti-snRNP, MCP-1, and CXCL1 were reduced in pristane-treated Psgl-1(-/-) mice compared to pristane-treated WT mice.	pristane	0-8	mast cell protease 1	Mus musculus	76-81
27357136-7	2016	Pristane-treated WT mice showed elevated anti-dsDNA, anti-snRNP, CXCL1, and MCP-1 levels compared to untreated mice; however levels of anti-snRNP, MCP-1, and CXCL1 were reduced in pristane-treated Psgl-1(-/-) mice compared to pristane-treated WT mice.	pristane	0-8	LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated	Mus musculus	140-145
27357136-7	2016	Pristane-treated WT mice showed elevated anti-dsDNA, anti-snRNP, CXCL1, and MCP-1 levels compared to untreated mice; however levels of anti-snRNP, MCP-1, and CXCL1 were reduced in pristane-treated Psgl-1(-/-) mice compared to pristane-treated WT mice.	pristane	0-8	mast cell protease 1	Mus musculus	147-152
27357136-7	2016	Pristane-treated WT mice showed elevated anti-dsDNA, anti-snRNP, CXCL1, and MCP-1 levels compared to untreated mice; however levels of anti-snRNP, MCP-1, and CXCL1 were reduced in pristane-treated Psgl-1(-/-) mice compared to pristane-treated WT mice.	pristane	0-8	chemokine (C-X-C motif) ligand 1	Mus musculus	158-163
27357136-7	2016	Pristane-treated WT mice showed elevated anti-dsDNA, anti-snRNP, CXCL1, and MCP-1 levels compared to untreated mice; however levels of anti-snRNP, MCP-1, and CXCL1 were reduced in pristane-treated Psgl-1(-/-) mice compared to pristane-treated WT mice.	pristane	0-8	selectin, platelet (p-selectin) ligand	Mus musculus	197-203
27357136-8	2016	Infiltration of neutrophils and macrophages at the cerebral infarction site were reduced in pristane-treated Psgl-1(-/-) mice compared to pristane-treated WT mice.	pristane	92-100	selectin, platelet (p-selectin) ligand	Mus musculus	109-115
26556607-14	2016	MicroRNA-155 silencing dampened pristane-induced ectopic activation of multiple inflammatory pathways and reduced the expression of proinflammatory cytokines.	pristane	32-40	microRNA 155	Mus musculus	0-12
26556607-15	2016	Several negative regulators of NF-kappaB signaling were inhibited by pristane and were reactivated in miR-155(-/-) mice.	pristane	69-77	microRNA 155	Mus musculus	102-109
26556607-17	2016	CONCLUSION: MicroRNA-155 promotes pristane-induced lung inflammation.	pristane	34-42	microRNA 155	Mus musculus	12-24
26773156-0	2016	C1q Modulates the Response to TLR7 Stimulation by Pristane-Primed Macrophages: Implications for Pristane-Induced Lupus.	pristane	50-58	toll-like receptor 7	Mus musculus	30-34
26773156-0	2016	C1q Modulates the Response to TLR7 Stimulation by Pristane-Primed Macrophages: Implications for Pristane-Induced Lupus.	pristane	96-104	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	0-3
26773156-2	2016	Intraperitoneal injection of pristane induces a lupus-like syndrome whose pathogenesis implicates the secretion of type I IFN by CD11b(+) Ly6C(high) inflammatory monocytes in a TLR7-dependent fashion.	pristane	29-37	integrin alpha M	Mus musculus	129-134
26773156-2	2016	Intraperitoneal injection of pristane induces a lupus-like syndrome whose pathogenesis implicates the secretion of type I IFN by CD11b(+) Ly6C(high) inflammatory monocytes in a TLR7-dependent fashion.	pristane	29-37	lymphocyte antigen 6 complex, locus C1	Mus musculus	138-142
26773156-2	2016	Intraperitoneal injection of pristane induces a lupus-like syndrome whose pathogenesis implicates the secretion of type I IFN by CD11b(+) Ly6C(high) inflammatory monocytes in a TLR7-dependent fashion.	pristane	29-37	toll-like receptor 7	Mus musculus	177-181
26773156-4	2016	In this study, we explored whether C1q deficiency could affect pristane-induced lupus.	pristane	63-71	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	35-38
26773156-6	2016	In keeping with the clinical scores, 2 wk after pristane injection the peritoneal recruitment of CD11b(+) Ly6C(high) inflammatory monocytes in C1qa(-/-) mice was impaired.	pristane	48-56	integrin alpha M	Mus musculus	97-102
26773156-6	2016	In keeping with the clinical scores, 2 wk after pristane injection the peritoneal recruitment of CD11b(+) Ly6C(high) inflammatory monocytes in C1qa(-/-) mice was impaired.	pristane	48-56	lymphocyte antigen 6 complex, locus C1	Mus musculus	106-110
26773156-6	2016	In keeping with the clinical scores, 2 wk after pristane injection the peritoneal recruitment of CD11b(+) Ly6C(high) inflammatory monocytes in C1qa(-/-) mice was impaired.	pristane	48-56	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	143-147
26773156-7	2016	Furthermore, C1q-deficient pristane-primed resident peritoneal macrophages secreted significantly less CCL3, CCL2, CXCL1, and IL-6 when stimulated in vitro with TLR7 ligand.	pristane	27-35	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	13-16
26773156-7	2016	Furthermore, C1q-deficient pristane-primed resident peritoneal macrophages secreted significantly less CCL3, CCL2, CXCL1, and IL-6 when stimulated in vitro with TLR7 ligand.	pristane	27-35	chemokine (C-C motif) ligand 3	Mus musculus	103-107
26773156-7	2016	Furthermore, C1q-deficient pristane-primed resident peritoneal macrophages secreted significantly less CCL3, CCL2, CXCL1, and IL-6 when stimulated in vitro with TLR7 ligand.	pristane	27-35	chemokine (C-C motif) ligand 2	Mus musculus	109-113
26773156-7	2016	Furthermore, C1q-deficient pristane-primed resident peritoneal macrophages secreted significantly less CCL3, CCL2, CXCL1, and IL-6 when stimulated in vitro with TLR7 ligand.	pristane	27-35	chemokine (C-X-C motif) ligand 1	Mus musculus	115-120
26773156-7	2016	Furthermore, C1q-deficient pristane-primed resident peritoneal macrophages secreted significantly less CCL3, CCL2, CXCL1, and IL-6 when stimulated in vitro with TLR7 ligand.	pristane	27-35	interleukin 6	Mus musculus	126-130
26773156-7	2016	Furthermore, C1q-deficient pristane-primed resident peritoneal macrophages secreted significantly less CCL3, CCL2, CXCL1, and IL-6 when stimulated in vitro with TLR7 ligand.	pristane	27-35	toll-like receptor 7	Mus musculus	161-165
26773156-8	2016	Replenishing C1q in vivo during the pristane-priming phase rectified this defect.	pristane	36-44	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	13-16
26773156-10	2016	These findings demonstrate that C1q deficiency impairs the TLR7-dependent chemokine production by pristane-primed peritoneal macrophages and suggest that C1q, and not C3, is involved in the handling of pristane by phagocytic cells, which is required to trigger disease in this model.	pristane	98-106	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	32-35
26773156-10	2016	These findings demonstrate that C1q deficiency impairs the TLR7-dependent chemokine production by pristane-primed peritoneal macrophages and suggest that C1q, and not C3, is involved in the handling of pristane by phagocytic cells, which is required to trigger disease in this model.	pristane	98-106	toll-like receptor 7	Mus musculus	59-63
26773156-10	2016	These findings demonstrate that C1q deficiency impairs the TLR7-dependent chemokine production by pristane-primed peritoneal macrophages and suggest that C1q, and not C3, is involved in the handling of pristane by phagocytic cells, which is required to trigger disease in this model.	pristane	98-106	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	154-157
26773156-10	2016	These findings demonstrate that C1q deficiency impairs the TLR7-dependent chemokine production by pristane-primed peritoneal macrophages and suggest that C1q, and not C3, is involved in the handling of pristane by phagocytic cells, which is required to trigger disease in this model.	pristane	202-210	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	32-35
26773156-10	2016	These findings demonstrate that C1q deficiency impairs the TLR7-dependent chemokine production by pristane-primed peritoneal macrophages and suggest that C1q, and not C3, is involved in the handling of pristane by phagocytic cells, which is required to trigger disease in this model.	pristane	202-210	toll-like receptor 7	Mus musculus	59-63
26773156-10	2016	These findings demonstrate that C1q deficiency impairs the TLR7-dependent chemokine production by pristane-primed peritoneal macrophages and suggest that C1q, and not C3, is involved in the handling of pristane by phagocytic cells, which is required to trigger disease in this model.	pristane	202-210	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	154-157
26405027-10	2016	Caspase-1-/- mice have a significant reduction in marginal zone B cell populations compared to WT 6 months after pristane exposure whereas T cell responses are intact in these mice.	pristane	113-121	caspase 1	Mus musculus	0-9
26525667-0	2016	Dietary extra virgin olive oil attenuates kidney injury in pristane-induced SLE model via activation of HO-1/Nrf-2 antioxidant pathway and suppression of JAK/STAT, NF-kappaB and MAPK activation.	pristane	59-67	heme oxygenase 1	Mus musculus	104-108
26525667-0	2016	Dietary extra virgin olive oil attenuates kidney injury in pristane-induced SLE model via activation of HO-1/Nrf-2 antioxidant pathway and suppression of JAK/STAT, NF-kappaB and MAPK activation.	pristane	59-67	nuclear factor, erythroid derived 2, like 2	Mus musculus	109-114
26525667-0	2016	Dietary extra virgin olive oil attenuates kidney injury in pristane-induced SLE model via activation of HO-1/Nrf-2 antioxidant pathway and suppression of JAK/STAT, NF-kappaB and MAPK activation.	pristane	59-67	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	164-173
26717913-5	2015	RESULTS: B cells with a switched "memory-like" (CD19(+)CD138(-)IgM(-)IgD(-)) (sMB) phenotype were increased in pristane-treated mice and expressed higher levels of Toll like receptor 7 (Tlr7) than cells with this phenotype from untreated mice.	pristane	111-119	small nuclear ribonucleoprotein B	Mus musculus	78-81
26717913-5	2015	RESULTS: B cells with a switched "memory-like" (CD19(+)CD138(-)IgM(-)IgD(-)) (sMB) phenotype were increased in pristane-treated mice and expressed higher levels of Toll like receptor 7 (Tlr7) than cells with this phenotype from untreated mice.	pristane	111-119	toll-like receptor 7	Mus musculus	164-184
26717913-5	2015	RESULTS: B cells with a switched "memory-like" (CD19(+)CD138(-)IgM(-)IgD(-)) (sMB) phenotype were increased in pristane-treated mice and expressed higher levels of Toll like receptor 7 (Tlr7) than cells with this phenotype from untreated mice.	pristane	111-119	toll-like receptor 7	Mus musculus	186-190
26717913-6	2015	Flow-sorted sMB cells from pristane-treated mice did not secrete IgG spontaneously, but were hyper-responsive to both synthetic (R848) and natural (apoptotic cells) TLR7 ligands, resulting in increased IgG production in vitro.	pristane	27-35	small nuclear ribonucleoprotein B	Mus musculus	12-15
26717913-6	2015	Flow-sorted sMB cells from pristane-treated mice did not secrete IgG spontaneously, but were hyper-responsive to both synthetic (R848) and natural (apoptotic cells) TLR7 ligands, resulting in increased IgG production in vitro.	pristane	27-35	toll-like receptor 7	Mus musculus	165-169
26717913-8	2015	Production of IgG was strongly inhibited by both JSH-23 and SB203580, suggesting that the canonical NFkappaB and p38 MAPK pathways, respectively, contribute to the TLR7 ligand hyper-responsiveness of sMB from pristane-treated mice.	pristane	209-217	toll-like receptor 7	Mus musculus	164-168
26717913-9	2015	CONCLUSIONS: The switched memory B cell subset from pristane-treated mice is expanded and shows an increased propensity to undergo terminal (plasma cell) differentiation in response to synthetic and natural TLR7 ligands.	pristane	52-60	toll-like receptor 7	Mus musculus	207-211
26405027-0	2016	Caspase-1 is required for maintenance of marginal zone B cells in pristane-induced lupus.	pristane	66-74	caspase 1	Mus musculus	0-9
26097482-3	2015	In contrast, pristane-induced lupus exhibits a prominent TLR7-dependent interferon signature.	pristane	13-21	toll like receptor 7	Homo sapiens	57-61
26405027-1	2016	OBJECTIVE: Caspase-1 is required for nephritis and robust autoantibody development in the pristane model of murine lupus.	pristane	90-98	caspase 1	Mus musculus	11-20
26600548-1	2015	This study aimed to investigate the relationship between type I interferon (IFN-I) and plaque stability in pristane-treated apolipoprotein E-knockout (ApoE(-/-)) mice.	pristane	107-115	apolipoprotein E	Mus musculus	124-140
26600548-6	2015	We found that pristane-treated ApoE(-/-) mice developed a lupus-like syndrome characterized by an increased production of serum ANA and ENA.	pristane	14-22	apolipoprotein E	Mus musculus	31-35
26600548-10	2015	We concluded that the vulnerability of plaques was associated with the activation of IFN-I in pristane-treated ApoE(-/-) mice.	pristane	94-102	apolipoprotein E	Mus musculus	111-115
26572128-0	2015	Differential development of oil granulomas induced by pristane injection in galectin-3 deficient mice.	pristane	54-62	lectin, galactose binding, soluble 3	Mus musculus	76-86
26572128-4	2015	Here, we have analyzed the role of galectin-3 in inflammatory cells mobilization and organization after pristane injection characterizing granulomatous reaction through the formation of oil granulomas.	pristane	104-112	lectin, galactose binding, soluble 3	Mus musculus	35-45
26770333-9	2015	CONCLUSION/SIGNIFICANCE: Our data indicated that induction of A20 overexpression inhibited pristane induced lupus inflammation and renal injury in mice and may be a new therapeutic strategy for treatment of lupus nephritis.	pristane	91-99	tumor necrosis factor, alpha-induced protein 3	Mus musculus	62-65
25777776-0	2015	Suppression of Autoimmunity and Renal Disease in Pristane-Induced Lupus by Myeloperoxidase.	pristane	49-57	myeloperoxidase	Mus musculus	75-90
25777776-4	2015	METHODS: LN was induced in C57BL/6 wild-type (WT) and MPO knockout (MPO(-/-) ) mice by intraperitoneal injection of pristane.	pristane	116-124	myeloperoxidase	Mus musculus	54-57
25777776-11	2015	CONCLUSION: MPO attenuates pristane-induced LN by inhibiting early inflammatory responses in the peritoneum and limiting the generation of CD4+ T cell autoimmunity in secondary lymphoid organs.	pristane	27-35	myeloperoxidase	Mus musculus	12-15
25533241-0	2015	Pristane primed rat T cells enhance TLR3 expression of fibroblast-like synoviocytes via TNF-alpha initiated p38 MAPK and NF-kappaB pathways.	pristane	0-8	toll-like receptor 3	Rattus norvegicus	36-40
25891969-8	2015	RESULTS: Pristane induced LN more strikingly in Bsg(-/-) mice than in Bsg(+/+) mice, even though humoral autoimmunity was similarly increased in both genotypes.	pristane	9-17	basigin	Mus musculus	48-51
25533241-0	2015	Pristane primed rat T cells enhance TLR3 expression of fibroblast-like synoviocytes via TNF-alpha initiated p38 MAPK and NF-kappaB pathways.	pristane	0-8	tumor necrosis factor	Rattus norvegicus	88-97
25533241-1	2015	Based on pristane-induced arthritis (PIA), we found that T cells mediate TLR3 overexpression in fibroblast-like synoviocytes (FLS).	pristane	9-17	toll-like receptor 3	Rattus norvegicus	73-77
25533241-3	2015	Rat FLS were co-cultured with pristane primed T cell conditioned medium (PPT medium), and TLR3 expression of FLS was significantly induced.	pristane	30-38	tachykinin, precursor 1	Rattus norvegicus	73-76
25533241-3	2015	Rat FLS were co-cultured with pristane primed T cell conditioned medium (PPT medium), and TLR3 expression of FLS was significantly induced.	pristane	30-38	toll-like receptor 3	Rattus norvegicus	90-94
25533241-9	2015	Summarily, TNF-alpha derived from pristane primed T cells induced TLR3 expression of FLS through activating p38 MAPK and NF-kappaB pathways.	pristane	34-42	tumor necrosis factor	Rattus norvegicus	11-20
25533241-9	2015	Summarily, TNF-alpha derived from pristane primed T cells induced TLR3 expression of FLS through activating p38 MAPK and NF-kappaB pathways.	pristane	34-42	toll-like receptor 3	Rattus norvegicus	66-70
25535966-4	2014	Pristane-induced lupus was induced in female wild type (WT) and cathelicidin-deficient (CRAMP-/-) mice.	pristane	0-8	cathelicidin antimicrobial peptide	Mus musculus	88-93
25252121-3	2015	METHODS: Toll-like receptor 7 (TLR-7) ligand-driven lupus was induced by injection of pristane into C57BL/6 (B6) mice deficient in TNFalpha (TNFalpha(-/-) ) or TNFalpha-intact B6 mice as wild-type controls.	pristane	86-94	toll-like receptor 7	Mus musculus	9-29
25252121-3	2015	METHODS: Toll-like receptor 7 (TLR-7) ligand-driven lupus was induced by injection of pristane into C57BL/6 (B6) mice deficient in TNFalpha (TNFalpha(-/-) ) or TNFalpha-intact B6 mice as wild-type controls.	pristane	86-94	toll-like receptor 7	Mus musculus	31-36
25252121-3	2015	METHODS: Toll-like receptor 7 (TLR-7) ligand-driven lupus was induced by injection of pristane into C57BL/6 (B6) mice deficient in TNFalpha (TNFalpha(-/-) ) or TNFalpha-intact B6 mice as wild-type controls.	pristane	86-94	tumor necrosis factor	Homo sapiens	141-149
25252121-3	2015	METHODS: Toll-like receptor 7 (TLR-7) ligand-driven lupus was induced by injection of pristane into C57BL/6 (B6) mice deficient in TNFalpha (TNFalpha(-/-) ) or TNFalpha-intact B6 mice as wild-type controls.	pristane	86-94	tumor necrosis factor	Mus musculus	141-149
25252121-7	2015	When treated with pristane, TNFalpha(-/-) mice developed more severe lupus compared to pristane-treated controls, characterized by increased levels of anti-Sm/RNP autoantibodies, type I IFN, PDCs, and peritoneal inflammatory (Ly-6C(high) ) monocytes.	pristane	18-26	tumor necrosis factor	Homo sapiens	28-36
25252121-7	2015	When treated with pristane, TNFalpha(-/-) mice developed more severe lupus compared to pristane-treated controls, characterized by increased levels of anti-Sm/RNP autoantibodies, type I IFN, PDCs, and peritoneal inflammatory (Ly-6C(high) ) monocytes.	pristane	18-26	lymphocyte antigen 6 complex, locus C1	Mus musculus	226-231
25252121-7	2015	When treated with pristane, TNFalpha(-/-) mice developed more severe lupus compared to pristane-treated controls, characterized by increased levels of anti-Sm/RNP autoantibodies, type I IFN, PDCs, and peritoneal inflammatory (Ly-6C(high) ) monocytes.	pristane	87-95	tumor necrosis factor	Homo sapiens	28-36
25252121-8	2015	In pristane-treated TNFalpha(-/-) mice, the numbers of neutrophils, a cell type that promotes resolution of inflammation, were decreased considerably, whereas the responses of inflammatory monocytes and PDCs and the production of type I IFN were increased and prolonged.	pristane	3-11	tumor necrosis factor	Homo sapiens	20-28
25252121-10	2015	However, this does not necessarily lead to type I IFN production or autoimmunity unless there is concomitant exposure to endogenous TLR-7 ligands, which are released from dead cells following pristane treatment.	pristane	192-200	toll-like receptor 7	Mus musculus	132-137
25252152-3	2015	METHODS: We compared KCa1.1 expression levels in FLS from rats with pristane-induced arthritis (PIA) and in FLS from healthy rats.	pristane	68-76	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	21-27
25281714-4	2014	In this study, we aimed to clarify the role of Mac-1 in pristane-induced DPH, using Mac-1(-/-) and wild-type (WT) mice on a C57BL/6 background.	pristane	56-64	integrin alpha M	Mus musculus	47-52
25281714-5	2014	After pristane injection, Mac-1(-/-) mice showed reduced prevalence of DPH and attenuated peritonitis compared with WT mice.	pristane	6-14	integrin alpha M	Mus musculus	26-31
25281714-8	2014	Depletion of neutrophils and eosinophils or adoptive transfer of classically activated macrophages resulted in the exacerbation of pristane-mediated DPH in both WT and Mac-1(-/-) mice.	pristane	131-139	integrin alpha M	Mus musculus	168-173
25281714-10	2014	Collectively, Mac-1 promoted acute inflammatory responses in the peritoneal cavity and the lungs by downregulating granulocyte migration and subsequent phenotypic conversion of macrophages in a pristane-induced systemic lupus erythematosus model.	pristane	194-202	integrin alpha M	Mus musculus	14-19
24992143-6	2014	Caspase-1, the central enzyme of the inflammasome, is essential for the development of type I interferon responses, autoantibody production, and nephritis in the pristane model of lupus.	pristane	162-170	caspase 1	Mus musculus	0-9
24971701-0	2014	Serum autoantibodies in pristane induced lupus are regulated by neutrophil gelatinase associated lipocalin.	pristane	24-32	lipocalin 2	Mus musculus	64-106
24528105-3	2014	These studies sought to define the role of IL-17A in experimental lupus induced by pristane administration.	pristane	83-91	interleukin 17A	Mus musculus	43-49
24971701-3	2014	Here, we describe a novel mechanism relating to the regulatory role of Neutrophil Gelatinase Associated Lipocalin (NGAL) in modulating the levels of autoantibodies in pristane induced lupus.	pristane	167-175	lipocalin 2	Mus musculus	71-113
24971701-3	2014	Here, we describe a novel mechanism relating to the regulatory role of Neutrophil Gelatinase Associated Lipocalin (NGAL) in modulating the levels of autoantibodies in pristane induced lupus.	pristane	167-175	lipocalin 2	Mus musculus	115-119
24971701-4	2014	Following a single injection of pristane intraperitoneally, NGAL expression was induced in both the serum and spleen.	pristane	32-40	lipocalin 2	Mus musculus	60-64
24971701-5	2014	Furthermore, NGAL deficient mice were more susceptible to the induction of pristane stimulated autoimmunity, and displayed higher numbers of autoantibody secreting cells and increased expression of activation induced cytidine deaminase (AID) and other inflammatory mediators in the spleen.	pristane	75-83	lipocalin 2	Mus musculus	13-17
24920843-3	2014	The induction of SLE by pristane in IL-17-sufficient wild-type mice did not occur in IL-17-deficient mice, which were protected from development of lupus autoantibodies and glomerulonephritis.	pristane	24-32	interleukin 17A	Mus musculus	36-41
24528105-4	2014	Pristane was administered to wild-type (WT) and IL-17A(-/-) mice.	pristane	0-8	interleukin 17A	Mus musculus	48-54
24528105-6	2014	IL-17A production increased significantly 6 days after pristane injection, with innate immune cells, neutrophils (Ly6G(+)) and macrophages (F4/80(+)) being the predominant source of IL-17A.	pristane	55-63	interleukin 17A	Mus musculus	0-6
24528105-8	2014	Seven months after pristane treatment humoral autoimmunity was diminished in the absence of IL-17A, with decreased levels of immunoglobulin (Ig)G and anti-dsDNA antibodies.	pristane	19-27	interleukin 17A	Mus musculus	92-98
24740500-7	2014	Accordingly, Nr4a1 mediated the anti-inflammatory properties of ACs in vivo and was required for maintenance of self-tolerance in the murine model of pristane-induced lupus.	pristane	150-158	nuclear receptor subfamily 4, group A, member 1	Mus musculus	13-18
23450347-0	2013	Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.	pristane	97-105	toll-like receptor 2	Mus musculus	0-20
24944605-12	2014	Therefore, the results of the present study indicate that DHMEQ has a beneficial effect on pristane-induced lupus through regulating cytokine levels and the MAPK/JNK/NF-kappaB signaling pathway.	pristane	91-99	mitogen-activated protein kinase 8	Mus musculus	162-165
24449581-9	2014	TNFalpha production was abolished in pristane-treated TLR-7(-/-) and mumt mice but was restored in mumt mice by infusing normal plasma.	pristane	37-45	tumor necrosis factor	Mus musculus	0-8
24449581-9	2014	TNFalpha production was abolished in pristane-treated TLR-7(-/-) and mumt mice but was restored in mumt mice by infusing normal plasma.	pristane	37-45	toll-like receptor 7	Mus musculus	54-59
24449581-10	2014	Pristane-treated WT and IFNAR(-/-) mice developed anemia, BM hypocellularity, and extramedullary hematopoiesis, which were absent in TLR-7(-/-) and TNFalpha(-/-) mice.	pristane	0-8	toll-like receptor 7	Mus musculus	133-138
24449581-10	2014	Pristane-treated WT and IFNAR(-/-) mice developed anemia, BM hypocellularity, and extramedullary hematopoiesis, which were absent in TLR-7(-/-) and TNFalpha(-/-) mice.	pristane	0-8	tumor necrosis factor	Mus musculus	148-156
24449581-11	2014	Additionally, the expression of CXCL12, which is produced by stromal cells and mediates homing of hematopoietic cells and plasmablasts, was decreased in BM from pristane-treated WT mice but was normal in BM from pristane-treated TNFalpha(-/-) mice.	pristane	161-169	chemokine (C-X-C motif) ligand 12	Mus musculus	32-38
24449581-11	2014	Additionally, the expression of CXCL12, which is produced by stromal cells and mediates homing of hematopoietic cells and plasmablasts, was decreased in BM from pristane-treated WT mice but was normal in BM from pristane-treated TNFalpha(-/-) mice.	pristane	161-169	tumor necrosis factor	Mus musculus	229-237
24449581-11	2014	Additionally, the expression of CXCL12, which is produced by stromal cells and mediates homing of hematopoietic cells and plasmablasts, was decreased in BM from pristane-treated WT mice but was normal in BM from pristane-treated TNFalpha(-/-) mice.	pristane	212-220	chemokine (C-X-C motif) ligand 12	Mus musculus	32-38
24449582-3	2014	Using the mouse model of pristane-induced lupus, we undertook this study to explore whether caspase 1, the central enzyme of the inflammasome, plays a role in the development of SLE and its associated vascular dysfunction.	pristane	25-33	caspase 1	Mus musculus	92-101
24449582-6	2014	RESULTS: While WT mice exposed to pristane developed autoantibodies and a strong type I interferon response, mice lacking caspase 1 were significantly protected against these features as well as against pristane-induced vascular dysfunction.	pristane	203-211	caspase 1	Mus musculus	122-131
24449582-7	2014	Further, the development of immune complex glomerulonephritis, which was prominent after pristane exposure in WT mice, was significantly abrogated in caspase 1(-/-) mice.	pristane	89-97	caspase 1	Mus musculus	150-159
25136646-5	2014	We found that pristane treatment for a period of 12 or 24 weeks triggered macrophage activation syndrome, characterized by hemophagocytosis in spleen and peripheral blood, enhanced lipid phagocytosis by peritoneal macrophages in vitro, erythropenia and leucopenia, increased anti-Smith, lactic dehydrogenase, triglyceride, and ferritin, as well as hypercytokinemia of IFN-gamma, TNF-alpha, IL-4, and IL-6.	pristane	14-22	interferon gamma	Mus musculus	368-377
25136646-5	2014	We found that pristane treatment for a period of 12 or 24 weeks triggered macrophage activation syndrome, characterized by hemophagocytosis in spleen and peripheral blood, enhanced lipid phagocytosis by peritoneal macrophages in vitro, erythropenia and leucopenia, increased anti-Smith, lactic dehydrogenase, triglyceride, and ferritin, as well as hypercytokinemia of IFN-gamma, TNF-alpha, IL-4, and IL-6.	pristane	14-22	tumor necrosis factor	Mus musculus	379-388
25136646-5	2014	We found that pristane treatment for a period of 12 or 24 weeks triggered macrophage activation syndrome, characterized by hemophagocytosis in spleen and peripheral blood, enhanced lipid phagocytosis by peritoneal macrophages in vitro, erythropenia and leucopenia, increased anti-Smith, lactic dehydrogenase, triglyceride, and ferritin, as well as hypercytokinemia of IFN-gamma, TNF-alpha, IL-4, and IL-6.	pristane	14-22	interleukin 4	Mus musculus	390-394
25136646-5	2014	We found that pristane treatment for a period of 12 or 24 weeks triggered macrophage activation syndrome, characterized by hemophagocytosis in spleen and peripheral blood, enhanced lipid phagocytosis by peritoneal macrophages in vitro, erythropenia and leucopenia, increased anti-Smith, lactic dehydrogenase, triglyceride, and ferritin, as well as hypercytokinemia of IFN-gamma, TNF-alpha, IL-4, and IL-6.	pristane	14-22	interleukin 6	Mus musculus	400-404
25136646-8	2014	Our data indicate that pristane administration induces macrophage activation, oxidative stress, and Th1/Th2 skewness, which can be attenuated by chloroquine.	pristane	23-31	negative elongation factor complex member C/D, Th1l	Mus musculus	100-103
25136646-8	2014	Our data indicate that pristane administration induces macrophage activation, oxidative stress, and Th1/Th2 skewness, which can be attenuated by chloroquine.	pristane	23-31	heart and neural crest derivatives expressed 2	Mus musculus	104-107
24260235-4	2013	In this study, we revealed an essential role of retinoid-related orphan receptor gamma t (RORgammat) in sustaining the recruitment of macrophages following pristane treatment.	pristane	156-164	RAR related orphan receptor C	Homo sapiens	48-86
24505471-0	2014	Pristane-induced arthritis loci interact with the Slc11a1 gene to determine susceptibility in mice selected for high inflammation.	pristane	0-8	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	Mus musculus	50-57
24423102-2	2014	This study was performed to determine the relationship between miR-26a and TLR3 in rat macrophages and to observe effects of miR-26a mimic on pristane induced arthritis (PIA) in rats.	pristane	142-150	microRNA 26a	Rattus norvegicus	125-132
24423102-6	2014	Expressions of TLR3 and miR-26a were detected during rat bone marrow derived macrophage (BMDM) induction, in pristane stimulated NR8383 cells and spleens from methotrexate (MTX) treated PIA rats.	pristane	109-117	toll-like receptor 3	Rattus norvegicus	15-19
24423102-6	2014	Expressions of TLR3 and miR-26a were detected during rat bone marrow derived macrophage (BMDM) induction, in pristane stimulated NR8383 cells and spleens from methotrexate (MTX) treated PIA rats.	pristane	109-117	microRNA 26a	Rattus norvegicus	24-31
24423102-10	2014	The alteration of miR-26a expression was negatively related with TLR3 expression during BMDM induction, in pristane-primed NR8383 cells and PIA rat spleens.	pristane	107-115	microRNA 26a	Rattus norvegicus	18-25
24423102-10	2014	The alteration of miR-26a expression was negatively related with TLR3 expression during BMDM induction, in pristane-primed NR8383 cells and PIA rat spleens.	pristane	107-115	toll-like receptor 3	Rattus norvegicus	65-69
24423102-12	2014	The miR-26a mimic treatment displayed the depression of TLR3 expression and ameliorated the disease severity in the rats with pristane induced arthritis.	pristane	126-134	microRNA 26a	Rattus norvegicus	4-11
23918976-0	2013	Overexpression of membrane-bound fas ligand (CD95L) exacerbates autoimmune disease and renal pathology in pristane-induced lupus.	pristane	106-114	Fas ligand (TNF superfamily, member 6)	Mus musculus	45-50
23918976-11	2013	These results demonstrate that FasL promotes inflammation in TMPD-induced autoimmunity, and its cleavage limits FasL proinflammatory activity.	pristane	61-65	Fas ligand (TNF superfamily, member 6)	Mus musculus	31-35
23695883-0	2013	Arthritis severity locus Cia4 is an early regulator of IL-6, IL-1beta, and NF-kappaB activators" expression in pristane-induced arthritis.	pristane	111-119	Collagen induced arthritis QTL 4	Rattus norvegicus	25-29
23695883-0	2013	Arthritis severity locus Cia4 is an early regulator of IL-6, IL-1beta, and NF-kappaB activators" expression in pristane-induced arthritis.	pristane	111-119	interleukin 6	Rattus norvegicus	55-59
23695883-0	2013	Arthritis severity locus Cia4 is an early regulator of IL-6, IL-1beta, and NF-kappaB activators" expression in pristane-induced arthritis.	pristane	111-119	interleukin 1 beta	Rattus norvegicus	61-69
23695883-1	2013	Cia4 is a locus on rat chromosome 7 that regulates disease severity and joint damage in models of rheumatoid arthritis, including pristane-induced arthritis (PIA).	pristane	130-138	Collagen induced arthritis QTL 4	Rattus norvegicus	0-4
23172753-5	2013	Expression of the rat cathelicidin rCRAMP and defensins was characterised in joints, blood and secondary lymphoid organs during pristane-induced arthritis (PIA) in rats and in a transfer model of PIA induced by CD4 T cells.	pristane	128-136	cathelicidin antimicrobial peptide	Rattus norvegicus	35-41
23172753-11	2013	After pristane injection, the increased expression of rCRAMP coincided with higher levels of cell death, raised levels of interferon (IFN)alpha and development of autoantibodies.	pristane	6-14	cathelicidin antimicrobial peptide	Rattus norvegicus	54-60
23450347-3	2013	The objective of this study was to investigate whether TLR-2 signaling is required for the induction of autoantibodies and the development of SLE-like disease in murine pristane-induced lupus.	pristane	169-177	toll-like receptor 2	Mus musculus	55-60
23450347-4	2013	METHODS: Lupus-like disease in C57BL/6 and TLR-2(-/-) mice was induced by pristane injection.	pristane	74-82	toll-like receptor 2	Mus musculus	43-48
23450347-7	2013	RESULTS: Pristane-injected TLR-2(-/-) mice generated reduced numbers of splenic CD138+/cytoplasmic kappaL/lambdaL chain-positive plasma cells and displayed diminished IgG responses against double-stranded DNA, histones, nucleosomes, some extractable nuclear autoantigens, and cardiolipin when compared with wild- type controls.	pristane	9-17	toll-like receptor 2	Mus musculus	27-32
23450347-8	2013	TLR-2 deficiency prevented the pristane-induced systemic release of interleukin-6 (IL-6) and IL-10.	pristane	31-39	toll-like receptor 2	Mus musculus	0-5
23450347-8	2013	TLR-2 deficiency prevented the pristane-induced systemic release of interleukin-6 (IL-6) and IL-10.	pristane	31-39	interleukin 6	Mus musculus	68-81
23450347-8	2013	TLR-2 deficiency prevented the pristane-induced systemic release of interleukin-6 (IL-6) and IL-10.	pristane	31-39	interleukin 6	Mus musculus	83-87
23450347-8	2013	TLR-2 deficiency prevented the pristane-induced systemic release of interleukin-6 (IL-6) and IL-10.	pristane	31-39	interleukin 10	Mus musculus	93-98
23450347-10	2013	Importantly, the renal disease that developed in pristane-treated TLR-2(-/-) mice was less severe than that in control mice, as reflected by milder proteinuria, reduced glomerular deposition of IgG and complement, and decreased renal infiltration of autoantibody-secreting cells.	pristane	49-57	toll-like receptor 2	Mus musculus	66-71
23450347-11	2013	CONCLUSION: TLR-2 is required for the production of prototypical lupus autoantibodies and the development of renal disease in pristane-induced murine lupus.	pristane	126-134	toll-like receptor 2	Mus musculus	12-17
23249408-0	2012	The arthritis severity locus Cia5a regulates the expression of inflammatory mediators including Syk pathway genes and proteases in pristane-induced arthritis.	pristane	131-139	spleen associated tyrosine kinase	Rattus norvegicus	96-99
23249408-1	2012	BACKGROUND: Cia5a is a locus on rat chromosome 10 that regulates disease severity and joint damage in two models of rheumatoid arthritis, collagen- and pristane-induced arthritis (PIA).	pristane	152-160	Collagen induced arthritis QTL 5	Rattus norvegicus	12-16
22917079-6	2012	Because levels of interleukin (IL)-1beta were elevated in sera of pristane-injected rats, with levels mirroring the course of PIA, we examined the effect of pristane at single cell level in vitro, using rat splenocytes and the human monocytic cell line THP-1.	pristane	66-74	interleukin 1 beta	Rattus norvegicus	18-40
22917079-7	2012	Pristane and other hydrocarbon oils induced IL-1beta secretion in THP-1 cells as well as in rat splenocytes.	pristane	0-8	interleukin 1 beta	Homo sapiens	44-52
22917079-7	2012	Pristane and other hydrocarbon oils induced IL-1beta secretion in THP-1 cells as well as in rat splenocytes.	pristane	0-8	GLI family zinc finger 2	Homo sapiens	66-71
22917079-9	2012	Elevated levels of IL-1alpha were also found in supernatants of cells treated with pristane and hexadecane.	pristane	83-91	interleukin 1 alpha	Rattus norvegicus	19-28
22917079-11	2012	The higher serum IL-1beta levels in pristane-injected animals might be caused by both inflammasome-dependent and -independent mechanisms, such as passive release from dying-cells and probably extracellular maturation of pro-IL-1beta.	pristane	36-44	interleukin 1 beta	Rattus norvegicus	17-25
22917079-11	2012	The higher serum IL-1beta levels in pristane-injected animals might be caused by both inflammasome-dependent and -independent mechanisms, such as passive release from dying-cells and probably extracellular maturation of pro-IL-1beta.	pristane	36-44	interleukin 1 beta	Rattus norvegicus	224-232
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	111-143	tumor necrosis factor	Mus musculus	38-46
22933628-0	2012	Monocytes from Irf5-/- mice have an intrinsic defect in their response to pristane-induced lupus.	pristane	74-82	interferon regulatory factor 5	Mus musculus	15-19
22933628-4	2012	In the present study, we examined the mechanisms by which loss of Irf5 protects mice from pristane-induced lupus at early time points of disease development.	pristane	90-98	interferon regulatory factor 5	Mus musculus	66-70
22933628-6	2012	Chemotaxis assays using peritoneal lavage from pristane-injected Irf5(+/+) and Irf5(-/-) littermates support an intrinsic defect in Irf5(-/-) monocytes.	pristane	47-55	interferon regulatory factor 5	Mus musculus	65-69
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	111-143	interferon alpha	Mus musculus	89-98
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	111-143	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	225-231
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	111-143	T cell immunoglobulin and mucin domain containing 4	Mus musculus	237-241
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	145-149	tumor necrosis factor	Mus musculus	38-46
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	145-149	interferon alpha	Mus musculus	89-98
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	145-149	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	225-231
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	145-149	T cell immunoglobulin and mucin domain containing 4	Mus musculus	237-241
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	165-173	tumor necrosis factor	Mus musculus	38-46
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	165-173	interferon alpha	Mus musculus	89-98
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	165-173	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	225-231
22723547-8	2012	Indeed, the administration of an anti-TNFalpha antibody or a reagent that stimulates the IFN-alpha production [2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane)] enhanced the production of autoantibodies in the MFG-E8- and Tim4-double-deficient mice.	pristane	165-173	T cell immunoglobulin and mucin domain containing 4	Mus musculus	237-241
22076633-0	2012	Identification of two new arthritis severity loci that regulate levels of autoantibodies, interleukin-1beta, and joint damage in pristane- and collagen-induced arthritis.	pristane	129-137	interleukin 1 beta	Rattus norvegicus	90-107
22702720-3	2012	TLR3 mRNA expression in spleen of both collagen-induced arthritis and pristane-induced arthritis (PIA) rats was increased significantly at 26 and 70 days after arthritis induction.	pristane	70-78	toll-like receptor 3	Rattus norvegicus	0-4
22702720-7	2012	However, in arthritis-resistant E3 rats injected with pristane, TLR3 expression of spleen was unaltered.	pristane	54-62	toll-like receptor 3	Rattus norvegicus	64-68
22933628-8	2012	Bone marrow reconstitution experiments further supported an intrinsic defect in Irf5(-/-) monocytes because Irf5(+/+) monocytes were preferentially recruited to the peritoneal cavity in response to pristane.	pristane	198-206	interferon regulatory factor 5	Mus musculus	108-112
22933628-9	2012	Taken together, these findings demonstrate an intrinsic role for IRF5 in the response of monocytes to pristane and their recruitment to the primary site of inflammation that is thought to trigger lupus onset in this experimental model of SLE.	pristane	102-110	interferon regulatory factor 5	Mus musculus	65-69
22307521-3	2012	The IgG antibody could down-regulate the expression of ISG15 and IFIT-1 induced by either recombinant IFN alpha 1b or naive IFN alpha from SLE patients" sera, and reduced total serum IgG and IgM antibodies level in a pristane-primed lupus-like mouse model.	pristane	217-225	ISG15 ubiquitin like modifier	Homo sapiens	55-60
22307521-3	2012	The IgG antibody could down-regulate the expression of ISG15 and IFIT-1 induced by either recombinant IFN alpha 1b or naive IFN alpha from SLE patients" sera, and reduced total serum IgG and IgM antibodies level in a pristane-primed lupus-like mouse model.	pristane	217-225	interferon induced protein with tetratricopeptide repeats 1	Homo sapiens	65-71
22307521-3	2012	The IgG antibody could down-regulate the expression of ISG15 and IFIT-1 induced by either recombinant IFN alpha 1b or naive IFN alpha from SLE patients" sera, and reduced total serum IgG and IgM antibodies level in a pristane-primed lupus-like mouse model.	pristane	217-225	interferon alpha 1	Homo sapiens	102-114
22307521-3	2012	The IgG antibody could down-regulate the expression of ISG15 and IFIT-1 induced by either recombinant IFN alpha 1b or naive IFN alpha from SLE patients" sera, and reduced total serum IgG and IgM antibodies level in a pristane-primed lupus-like mouse model.	pristane	217-225	interferon alpha 1	Homo sapiens	102-111
22076633-1	2012	OBJECTIVE: Cia3 is a locus on rat chromosome 4 that regulates severity and joint damage in collagen- and pristane-induced arthritis (CIA and PIA).	pristane	105-113	Collagen induced arthritis QTL 3	Rattus norvegicus	11-15
22422888-2	2012	In this study, we examined the role of IRF5 in the pathogenesis of pristane-induced lupus in mice.	pristane	67-75	interferon regulatory factor 5	Mus musculus	39-43
22422888-3	2012	The pathological response to pristane in IRF5(-/-) mice shared many features with type I IFN receptor (IFNAR)(-/-) and TLR7(-/-) mice: production of anti-Sm/RNP autoantibodies, glomerulonephritis, generation of Ly6C(hi) monocytes, and IFN-I production all were greatly attenuated.	pristane	29-37	interferon regulatory factor 5	Mus musculus	41-45
22422888-3	2012	The pathological response to pristane in IRF5(-/-) mice shared many features with type I IFN receptor (IFNAR)(-/-) and TLR7(-/-) mice: production of anti-Sm/RNP autoantibodies, glomerulonephritis, generation of Ly6C(hi) monocytes, and IFN-I production all were greatly attenuated.	pristane	29-37	lymphocyte antigen 6 complex, locus C1	Mus musculus	211-215
22422888-4	2012	Lymphocyte activation following pristane injection was greatly diminished in IRF5(-/-) mice, and Th cell differentiation was deviated from Th1 in wild-type mice toward Th2 in IRF5(-/-) mice.	pristane	32-40	interferon regulatory factor 5	Mus musculus	77-81
22422888-6	2012	Indeed, production of IFN-I, IL-12, and IL-23 in response to pristane was markedly decreased, whereas IL-4 increased.	pristane	61-69	interleukin 23, alpha subunit p19	Mus musculus	40-45
22422888-9	2012	Collectively, these data indicate that altered production of IFN-I and other cytokines in IRF5(-/-) mice prevents pristane from inducing lupus pathology by broadly affecting T and B lymphocyte activation/differentiation.	pristane	114-122	interferon regulatory factor 5	Mus musculus	90-94
21725847-2	2012	The aim of this study is to investigate the regulation and potential role of TLR2 in spleen of pristane-induced arthritis (PIA) rat, which can be used to further understand the mechanisms of RA.	pristane	95-103	toll-like receptor 2	Rattus norvegicus	77-81
22678902-0	2012	Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching.	pristane	39-47	interferon regulatory factor 5	Mus musculus	0-4
22678902-0	2012	Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching.	pristane	39-47	heart and neural crest derivatives expressed 2	Mus musculus	76-79
22678902-3	2012	Here, we demonstrate that IRF5 is required for pristane-induced SLE via its ability to control multiple facets of autoimmunity.	pristane	47-55	interferon regulatory factor 5	Mus musculus	26-30
21978690-4	2011	To investigate their potency for clinical use, we further administrated 4E5 to a mouse lupus-like disease model (C57BL/J6) induced by Pristane.	pristane	134-142	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	113-121
21896286-3	2011	Administration of pristane reduces the incidence and severity of IRBP-induced uveitis as demonstrated by the decrease in vasculitis and inflammatory foci in fundus and by a reduction in histological damages and leukocyte infiltration compared to untreated or phytol-treated mice.	pristane	18-26	retinol binding protein 3, interstitial	Mus musculus	65-69
21896286-4	2011	The protective effect observed is associated with a decreased activation of peripheral CD4+ and CD8+ T lymphocytes and a decrease in the intensity of the Th1 and Th17 autoimmune response to IRBP in pristane-treated mice compared to control mice, as evidenced by the decreased production of IFNgamma and IL17 by IRBP-specific lymphocytes from lymph nodes draining the site of immunization and by the increased production of anti-IRBP IgG1 over IgG2a.	pristane	198-206	CD4 antigen	Mus musculus	87-90
21896286-4	2011	The protective effect observed is associated with a decreased activation of peripheral CD4+ and CD8+ T lymphocytes and a decrease in the intensity of the Th1 and Th17 autoimmune response to IRBP in pristane-treated mice compared to control mice, as evidenced by the decreased production of IFNgamma and IL17 by IRBP-specific lymphocytes from lymph nodes draining the site of immunization and by the increased production of anti-IRBP IgG1 over IgG2a.	pristane	198-206	negative elongation factor complex member C/D, Th1l	Mus musculus	154-157
21896286-4	2011	The protective effect observed is associated with a decreased activation of peripheral CD4+ and CD8+ T lymphocytes and a decrease in the intensity of the Th1 and Th17 autoimmune response to IRBP in pristane-treated mice compared to control mice, as evidenced by the decreased production of IFNgamma and IL17 by IRBP-specific lymphocytes from lymph nodes draining the site of immunization and by the increased production of anti-IRBP IgG1 over IgG2a.	pristane	198-206	retinol binding protein 3, interstitial	Mus musculus	190-194
21896286-4	2011	The protective effect observed is associated with a decreased activation of peripheral CD4+ and CD8+ T lymphocytes and a decrease in the intensity of the Th1 and Th17 autoimmune response to IRBP in pristane-treated mice compared to control mice, as evidenced by the decreased production of IFNgamma and IL17 by IRBP-specific lymphocytes from lymph nodes draining the site of immunization and by the increased production of anti-IRBP IgG1 over IgG2a.	pristane	198-206	interferon gamma	Mus musculus	290-298
21896286-4	2011	The protective effect observed is associated with a decreased activation of peripheral CD4+ and CD8+ T lymphocytes and a decrease in the intensity of the Th1 and Th17 autoimmune response to IRBP in pristane-treated mice compared to control mice, as evidenced by the decreased production of IFNgamma and IL17 by IRBP-specific lymphocytes from lymph nodes draining the site of immunization and by the increased production of anti-IRBP IgG1 over IgG2a.	pristane	198-206	interleukin 17A	Mus musculus	303-307
21896286-4	2011	The protective effect observed is associated with a decreased activation of peripheral CD4+ and CD8+ T lymphocytes and a decrease in the intensity of the Th1 and Th17 autoimmune response to IRBP in pristane-treated mice compared to control mice, as evidenced by the decreased production of IFNgamma and IL17 by IRBP-specific lymphocytes from lymph nodes draining the site of immunization and by the increased production of anti-IRBP IgG1 over IgG2a.	pristane	198-206	retinol binding protein 3, interstitial	Mus musculus	311-315
21896286-4	2011	The protective effect observed is associated with a decreased activation of peripheral CD4+ and CD8+ T lymphocytes and a decrease in the intensity of the Th1 and Th17 autoimmune response to IRBP in pristane-treated mice compared to control mice, as evidenced by the decreased production of IFNgamma and IL17 by IRBP-specific lymphocytes from lymph nodes draining the site of immunization and by the increased production of anti-IRBP IgG1 over IgG2a.	pristane	198-206	retinol binding protein 3, interstitial	Mus musculus	311-315
21896286-4	2011	The protective effect observed is associated with a decreased activation of peripheral CD4+ and CD8+ T lymphocytes and a decrease in the intensity of the Th1 and Th17 autoimmune response to IRBP in pristane-treated mice compared to control mice, as evidenced by the decreased production of IFNgamma and IL17 by IRBP-specific lymphocytes from lymph nodes draining the site of immunization and by the increased production of anti-IRBP IgG1 over IgG2a.	pristane	198-206	immunoglobulin heavy variable V1-9	Mus musculus	443-448
21896286-6	2011	The benefit of lowering the systemic oxidative stress by pristane in the course of EAU was confirmed by injecting the antioxidant NAC in IRBP-immunized mice.	pristane	57-65	NLR family, pyrin domain containing 1A	Mus musculus	130-133
21896286-6	2011	The benefit of lowering the systemic oxidative stress by pristane in the course of EAU was confirmed by injecting the antioxidant NAC in IRBP-immunized mice.	pristane	57-65	retinol binding protein 3, interstitial	Mus musculus	137-141
21896286-7	2011	As pristane, NAC decreased clinical and histological inflammation of the retina and preserved the integrity of the hemato-retinal barrier.	pristane	3-11	NLR family, pyrin domain containing 1A	Mus musculus	13-16
21708001-14	2011	Rat FLSs co-cultured with pristane-primed T cells showed strengthened migration ability and significant upregulation of TLR3, IFN-beta, IL-6 and matrix metalloproteinase 3 (MMP3) expression, which could also be induced by pristane-primed, T-cell conditioned medium.	pristane	26-34	toll-like receptor 3	Rattus norvegicus	120-124
21439786-4	2011	Here, we report that splenocytes from rats with pristane-induced arthritis transfer disease after in vitro restimulation with hnRNP-A/B antigens.	pristane	48-56	heterogeneous nuclear ribonucleoprotein A/B	Rattus norvegicus	126-135
21708001-14	2011	Rat FLSs co-cultured with pristane-primed T cells showed strengthened migration ability and significant upregulation of TLR3, IFN-beta, IL-6 and matrix metalloproteinase 3 (MMP3) expression, which could also be induced by pristane-primed, T-cell conditioned medium.	pristane	26-34	interferon beta 1	Rattus norvegicus	126-134
21708001-14	2011	Rat FLSs co-cultured with pristane-primed T cells showed strengthened migration ability and significant upregulation of TLR3, IFN-beta, IL-6 and matrix metalloproteinase 3 (MMP3) expression, which could also be induced by pristane-primed, T-cell conditioned medium.	pristane	26-34	interleukin 6	Rattus norvegicus	136-140
21708001-14	2011	Rat FLSs co-cultured with pristane-primed T cells showed strengthened migration ability and significant upregulation of TLR3, IFN-beta, IL-6 and matrix metalloproteinase 3 (MMP3) expression, which could also be induced by pristane-primed, T-cell conditioned medium.	pristane	26-34	matrix metallopeptidase 3	Rattus norvegicus	145-171
21708001-14	2011	Rat FLSs co-cultured with pristane-primed T cells showed strengthened migration ability and significant upregulation of TLR3, IFN-beta, IL-6 and matrix metalloproteinase 3 (MMP3) expression, which could also be induced by pristane-primed, T-cell conditioned medium.	pristane	26-34	matrix metallopeptidase 3	Rattus norvegicus	173-177
21708001-14	2011	Rat FLSs co-cultured with pristane-primed T cells showed strengthened migration ability and significant upregulation of TLR3, IFN-beta, IL-6 and matrix metalloproteinase 3 (MMP3) expression, which could also be induced by pristane-primed, T-cell conditioned medium.	pristane	222-230	matrix metallopeptidase 3	Rattus norvegicus	145-171
21191074-4	2011	In this study, we reveal the essential role of IL-1alpha in sustaining the chronic recruitment of neutrophils following 2,6,10,14 tetramethylpentadecane treatment.	pristane	120-152	interleukin 1 alpha	Homo sapiens	47-56
21098093-7	2010	The production of high-affinity antibodies is reduced, and pristane-elicited autoantibodies and glomerulonephritis are significantly diminished, in Il27ra(-/-) mice.	pristane	59-67	interleukin 27 receptor, alpha	Mus musculus	148-154
21315035-9	2011	The percentage of peripheral and peritoneal IFN-alpha producing cells was much higher in pristane group than that of the PBS control group since 2 weeks after intraperitoneal injection.	pristane	89-97	interferon alpha	Mus musculus	44-53
21194185-0	2011	Methotrexate ameliorates pristane-induced arthritis by decreasing IFN-gamma and IL-17A expressions.	pristane	25-33	interferon gamma	Rattus norvegicus	66-75
21194185-0	2011	Methotrexate ameliorates pristane-induced arthritis by decreasing IFN-gamma and IL-17A expressions.	pristane	25-33	interleukin 17A	Rattus norvegicus	80-86
21194185-9	2011	CONCLUSIONS: MTX, but not BSO, can reduce the arthritis severity and decrease the mRNA expressions of IFN-gamma and IL-17A in pristane-induced arthritis of rats.	pristane	126-134	interferon gamma	Rattus norvegicus	102-111
21194185-9	2011	CONCLUSIONS: MTX, but not BSO, can reduce the arthritis severity and decrease the mRNA expressions of IFN-gamma and IL-17A in pristane-induced arthritis of rats.	pristane	126-134	interleukin 17A	Rattus norvegicus	116-122
20810248-0	2010	TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy.	pristane	86-94	toll-like receptor 9	Mus musculus	0-4
20810248-0	2010	TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy.	pristane	86-94	toll-like receptor 4	Mus musculus	9-13
20810248-7	2010	Compared to wild type mice treated with pristane, functional and histological renal injury and glomerular immunoglobulin and complement deposition was decreased in TLR9-/- mice.	pristane	40-48	toll-like receptor 9	Mus musculus	164-168
20810248-11	2010	These results demonstrate that both TLR9 and TLR4 are required for "full-blown" autoimmunity and organ injury in experimental lupus induced by pristane.	pristane	143-151	toll-like receptor 9	Mus musculus	36-40
20810248-11	2010	These results demonstrate that both TLR9 and TLR4 are required for "full-blown" autoimmunity and organ injury in experimental lupus induced by pristane.	pristane	143-151	toll-like receptor 4	Mus musculus	45-49
20112371-5	2010	In vivo, lack of SIGIRR increased surface CD40 expression on spleen CD11c(+) dendritic cells and MX-1, TNF, IL-12, BAFF and BCL-2 mRNA expression 6 months after pristane injection.	pristane	161-169	single Ig and TIR domain containing	Homo sapiens	17-23
20505148-8	2010	The decreased TNF potential and reduced proinflammatory macrophage phenotype in congenic rats was also associated with reduced clinical severity in experimental autoimmune encephalomyelitis, pristane-induced arthritis and sepsis experimental models.	pristane	191-199	tumor necrosis factor	Rattus norvegicus	14-17
20368280-4	2010	Prophylactic B cell depletion by repeated CD20 mAb treatments prolonged survival during pristane-accelerated lupus in NZB/W F(1) mice, whereas CD22 mAb had little effect.	pristane	88-96	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	42-46
20162378-6	2010	The best clone designated as MAN-1, was injected intraperitoneally to some Pristane-injected mice.	pristane	75-83	LEM domain containing 3	Homo sapiens	29-34
20804539-4	2010	T cell deficient mice (LAT(-/-) ) responded to pristane by developing serosal granuloma and mesenteric granuloma (MG) as in wild type mice.	pristane	47-55	linker for activation of T cells	Mus musculus	23-26
20804539-6	2010	However, even when a comparable number of B cells were present in the mesentery, the absence of TNFalpha resulted in similar defects in OG formation after pristane treatment, demonstrating that both B cells and TNFalpha are very crucial for pristane-induced OG formation.	pristane	241-249	tumor necrosis factor	Mus musculus	96-104
20804539-6	2010	However, even when a comparable number of B cells were present in the mesentery, the absence of TNFalpha resulted in similar defects in OG formation after pristane treatment, demonstrating that both B cells and TNFalpha are very crucial for pristane-induced OG formation.	pristane	241-249	tumor necrosis factor	Mus musculus	211-219
17122779-0	2007	Slc11a1 (formerly NRAMP1) gene modulates both acute inflammatory reactions and pristane-induced arthritis in mice.	pristane	79-87	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	Mus musculus	0-7
19066175-7	2009	Maximum linkage to pristane-induced arthritis occurred less than 130 kb from the known genetic arthritis determinants Ncf1 and APLEC, demonstrating remarkable mapping precision.	pristane	19-27	neutrophil cytosolic factor 1	Rattus norvegicus	118-122
19808647-4	2009	In chronic peritonitis induced by pristane, the persistent recruitment of Ly6C(hi) inflammatory monocytes into the peritoneum was abolished in type I interferon (IFN-I) receptor-deficient mice but was unaffected by the absence of IFN-gamma, tumor necrosis factor-alpha, interleukin-6, or interleukin-1.	pristane	34-42	lymphocyte antigen 6 complex, locus C1	Mus musculus	74-78
18266970-5	2008	Furthermore, the data showed that injection of carcinogenic compound, pristane (2, 6,10,14-tetramethylpen-tadecane) induces breast tumour progression leading to enhanced expression of OPN and other oncogenic molecules in mammary fat pad of nude- and wild-type mice but not in OPN-/- mice.	pristane	70-78	secreted phosphoprotein 1	Mus musculus	184-187
18266970-5	2008	Furthermore, the data showed that injection of carcinogenic compound, pristane (2, 6,10,14-tetramethylpen-tadecane) induces breast tumour progression leading to enhanced expression of OPN and other oncogenic molecules in mammary fat pad of nude- and wild-type mice but not in OPN-/- mice.	pristane	70-78	secreted phosphoprotein 1	Mus musculus	276-279
18266970-5	2008	Furthermore, the data showed that injection of carcinogenic compound, pristane (2, 6,10,14-tetramethylpen-tadecane) induces breast tumour progression leading to enhanced expression of OPN and other oncogenic molecules in mammary fat pad of nude- and wild-type mice but not in OPN-/- mice.	pristane	80-114	secreted phosphoprotein 1	Mus musculus	184-187
18266970-5	2008	Furthermore, the data showed that injection of carcinogenic compound, pristane (2, 6,10,14-tetramethylpen-tadecane) induces breast tumour progression leading to enhanced expression of OPN and other oncogenic molecules in mammary fat pad of nude- and wild-type mice but not in OPN-/- mice.	pristane	80-114	secreted phosphoprotein 1	Mus musculus	276-279
18266970-6	2008	However, intratumoural injection of OPN siRNA to pristane-induced tumour significantly suppressed these effects.	pristane	49-57	secreted phosphoprotein 1	Mus musculus	36-39
18383384-0	2008	Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis.	pristane	40-48	toll-like receptor 7	Mus musculus	15-35
18383384-3	2008	The purpose of this study was to investigate the role of TLR-7 in anti-snRNP antibody production and renal disease in SLE induced by an exogenous factor in the absence of genetic predisposition, using the pristane-induced murine lupus model.	pristane	205-213	toll-like receptor 7	Mus musculus	57-62
18383384-7	2008	RESULTS: We found that anti-snRNP antibody production induced by pristane treatment was entirely dependent on the expression of TLR-7, whereas anti-double-stranded DNA antibody production was not affected by a lack of TLR-7.	pristane	65-73	toll-like receptor 7	Mus musculus	128-133
18383384-9	2008	CONCLUSION: TLR-7 is specifically required for the production of RNA-reactive autoantibodies and the development of glomerulonephritis in pristane-induced murine lupus, a model of environmentally triggered SLE in the absence of genetic susceptibility to autoimmunity.	pristane	138-146	toll-like receptor 7	Mus musculus	12-17
18340381-3	2008	Here, we demonstrate that 2 IFN-I signaling molecules, IFN regulatory factor 9 (IRF9) and STAT1, were required for the production of IgG autoantibodies in the pristane-induced mouse model of SLE.	pristane	159-167	interferon regulatory factor 9	Mus musculus	55-78
18340381-3	2008	Here, we demonstrate that 2 IFN-I signaling molecules, IFN regulatory factor 9 (IRF9) and STAT1, were required for the production of IgG autoantibodies in the pristane-induced mouse model of SLE.	pristane	159-167	interferon regulatory factor 9	Mus musculus	80-84
18340381-3	2008	Here, we demonstrate that 2 IFN-I signaling molecules, IFN regulatory factor 9 (IRF9) and STAT1, were required for the production of IgG autoantibodies in the pristane-induced mouse model of SLE.	pristane	159-167	signal transducer and activator of transcription 1	Mus musculus	90-95
18340381-4	2008	In addition, levels of IgM autoantibodies were increased in pristane-treated Irf9 -/- mice, suggesting that IRF9 plays a role in isotype switching in response to self antigens.	pristane	60-68	interferon regulatory factor 9	Mus musculus	77-81
18340381-4	2008	In addition, levels of IgM autoantibodies were increased in pristane-treated Irf9 -/- mice, suggesting that IRF9 plays a role in isotype switching in response to self antigens.	pristane	60-68	interferon regulatory factor 9	Mus musculus	108-112
18354236-5	2008	In this study, we demonstrate that tetramethylpentadecane treatment induces an accumulation of immature Ly6C(high) monocytes, which are a major source of IFN-I in this lupus model.	pristane	35-57	lymphocyte antigen 6 complex, locus C1	Mus musculus	104-108
18025202-6	2007	CD4(+) lymph node cells isolated 10 days after pristane injection produced IFN-gamma but not IL-4 in response to stimulation with hnRNP-A2, whereas none of the other candidate Ags elicited cytokine secretion.	pristane	47-55	interferon gamma	Rattus norvegicus	75-84
17366741-4	2007	LPS-stimulated production of IL-6 and IL-10 by splenocytes and macrophages from pristane-induced lupus mice were remarkably up-regulated compared to normal mice, whereas production of macrophage TNF-alpha was significantly down-regulated.	pristane	80-88	interleukin 6	Mus musculus	29-33
17366741-4	2007	LPS-stimulated production of IL-6 and IL-10 by splenocytes and macrophages from pristane-induced lupus mice were remarkably up-regulated compared to normal mice, whereas production of macrophage TNF-alpha was significantly down-regulated.	pristane	80-88	interleukin 10	Mus musculus	38-43
20500834-0	2010	Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats.	pristane	99-107	toll-like receptor 3	Rattus norvegicus	0-20
20500834-10	2010	RESULTS: By screening the TLR expression profile in spleen of DA rats after pristane injection, we found that TLR3 was the most early and prominently upregulated TLR.	pristane	76-84	toll-like receptor 3	Rattus norvegicus	110-114
20500834-11	2010	Both TLR3 mRNA and protein expression of spleen were upregulated at 6 and 26 days after pristane injection.	pristane	88-96	toll-like receptor 3	Rattus norvegicus	5-9
20500834-13	2010	Particularly, TLR3 expression was induced in splenic macrophages of PIA rats, and also in the NR8383 cell line after pristane stimulation in a dose- and time- dependent manner.	pristane	117-125	toll-like receptor 3	Rattus norvegicus	14-18
20500834-14	2010	Upregulation of interferon beta (IFN-beta) and TNF-alpha by pristane stimulation was blocked by anti-TLR3 antibody in NR8383.	pristane	60-68	interferon beta 1	Rattus norvegicus	16-31
20500834-14	2010	Upregulation of interferon beta (IFN-beta) and TNF-alpha by pristane stimulation was blocked by anti-TLR3 antibody in NR8383.	pristane	60-68	interferon beta 1	Rattus norvegicus	33-41
20500834-14	2010	Upregulation of interferon beta (IFN-beta) and TNF-alpha by pristane stimulation was blocked by anti-TLR3 antibody in NR8383.	pristane	60-68	tumor necrosis factor	Rattus norvegicus	47-56
20500834-14	2010	Upregulation of interferon beta (IFN-beta) and TNF-alpha by pristane stimulation was blocked by anti-TLR3 antibody in NR8383.	pristane	60-68	toll-like receptor 3	Rattus norvegicus	101-105
19302140-6	2009	Here we review these advances and discuss the usage of pristane-induced mouse plasmacytomas as a tool to investigate the origin of Igh-cMyc translocations and B-cell tumorigenesis.	pristane	55-63	immunoglobulin heavy chain complex	Mus musculus	131-134
19302140-6	2009	Here we review these advances and discuss the usage of pristane-induced mouse plasmacytomas as a tool to investigate the origin of Igh-cMyc translocations and B-cell tumorigenesis.	pristane	55-63	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	135-139
19624844-3	2009	In the current study, we characterized the role of the IFNAR2 chain of the type I IFN (IFN-I) receptor in the targeting of nucleic acid-associated autoantigens and in B-cell expression of the nucleic acid-sensing Toll-like receptors (TLRs), TLR7 and TLR9, in the pristane model of lupus.	pristane	263-271	interferon (alpha and beta) receptor 2	Mus musculus	55-61
19624844-8	2009	RESULTS: Autoantigen microarray profiling revealed that pristane-treated IFNAR2-/- mice lacked autoantibodies directed against components of the RNA-associated autoantigen complexes Smith antigen/ribonucleoprotein (Sm/RNP) and ribosomal phosphoprotein P0 (RiboP).	pristane	56-64	interferon (alpha and beta) receptor 2	Mus musculus	73-79
19624844-9	2009	The level of IgG anti-single-stranded DNA and anti-histone autoantibodies in pristane-treated IFNAR2-/- mice was decreased compared to pristane-treated WT mice.	pristane	77-85	interferon (alpha and beta) receptor 2	Mus musculus	94-100
19047436-12	2008	We show that TMPD elicits IFN-I production, monocyte recruitment, and autoantibody production exclusively through a Toll-like receptor (TLR) 7- and myeloid differentiation factor 88 (MyD88)-dependent pathway.	pristane	13-17	toll-like receptor 7	Mus musculus	136-139
19047436-12	2008	We show that TMPD elicits IFN-I production, monocyte recruitment, and autoantibody production exclusively through a Toll-like receptor (TLR) 7- and myeloid differentiation factor 88 (MyD88)-dependent pathway.	pristane	13-17	myeloid differentiation primary response gene 88	Mus musculus	148-181
19047436-12	2008	We show that TMPD elicits IFN-I production, monocyte recruitment, and autoantibody production exclusively through a Toll-like receptor (TLR) 7- and myeloid differentiation factor 88 (MyD88)-dependent pathway.	pristane	13-17	myeloid differentiation primary response gene 88	Mus musculus	183-188
19047436-13	2008	In vitro studies revealed that TMPD augments the effect of TLR7 ligands but does not directly activate TLR7 itself.	pristane	31-35	toll-like receptor 7	Mus musculus	59-63
19047436-14	2008	The effects of TMPD were amplified by the Y-linked autoimmune acceleration cluster, which carries a duplication of the TLR7 gene.	pristane	15-19	toll-like receptor 7	Mus musculus	119-123
19047436-16	2008	Collectively, the data demonstrate that TMPD-stimulated IFN-I production requires TLR7/MyD88 signaling and is independent of autoantibody-mediated uptake of ribonucleoproteins by FcgammaRs.	pristane	40-44	toll-like receptor 7	Mus musculus	82-86
19047436-16	2008	Collectively, the data demonstrate that TMPD-stimulated IFN-I production requires TLR7/MyD88 signaling and is independent of autoantibody-mediated uptake of ribonucleoproteins by FcgammaRs.	pristane	40-44	myeloid differentiation primary response gene 88	Mus musculus	87-92
18449509-6	2008	Exogenous PGE(2) enhanced production of IL-6, IL-10, and NO but decreased TNF-alpha by macrophages and augmented IFN-gamma, IL-6, and IL-10 by splenocytes from pristane-induced lupus mice compared to healthy controls.	pristane	160-168	interferon gamma	Mus musculus	113-122
18449509-6	2008	Exogenous PGE(2) enhanced production of IL-6, IL-10, and NO but decreased TNF-alpha by macrophages and augmented IFN-gamma, IL-6, and IL-10 by splenocytes from pristane-induced lupus mice compared to healthy controls.	pristane	160-168	interleukin 10	Mus musculus	134-139
18449509-7	2008	Exogenous PGE(2) also enhanced production of IFN-gamma, IL-6, and IL-10 by thymocytes from pristane-induced lupus mice.	pristane	91-99	interferon gamma	Mus musculus	45-54
18449509-7	2008	Exogenous PGE(2) also enhanced production of IFN-gamma, IL-6, and IL-10 by thymocytes from pristane-induced lupus mice.	pristane	91-99	interleukin 10	Mus musculus	66-71
18449509-8	2008	Indomethacin (Indo), a PGE(2) synthesis inhibitor, greatly inhibited LPS-induced production of IL-6 and IL-10 by macrophages from pristane-induced lupus mice, while enhanced TNF-alpha.	pristane	130-138	interleukin 6	Mus musculus	95-99
18449509-8	2008	Indomethacin (Indo), a PGE(2) synthesis inhibitor, greatly inhibited LPS-induced production of IL-6 and IL-10 by macrophages from pristane-induced lupus mice, while enhanced TNF-alpha.	pristane	130-138	interleukin 10	Mus musculus	104-109
18449509-9	2008	Indo remarkably inhibited Con A-increased production of IFN-gamma, IL-6, and IL-10 by splenocytes and thymocytes from pristane-induced lupus mice.	pristane	118-126	interferon gamma	Mus musculus	56-65
18449509-9	2008	Indo remarkably inhibited Con A-increased production of IFN-gamma, IL-6, and IL-10 by splenocytes and thymocytes from pristane-induced lupus mice.	pristane	118-126	interleukin 6	Mus musculus	67-71
18449509-9	2008	Indo remarkably inhibited Con A-increased production of IFN-gamma, IL-6, and IL-10 by splenocytes and thymocytes from pristane-induced lupus mice.	pristane	118-126	interleukin 10	Mus musculus	77-82
17998390-2	2007	We asked if AID is required for accelerated tumor development in pristane-treated Bcl-xL transgenic BALB/c mice deficient in AID (pBxAicda-/-).	pristane	65-73	activation-induced cytidine deaminase	Mus musculus	12-15
17998390-2	2007	We asked if AID is required for accelerated tumor development in pristane-treated Bcl-xL transgenic BALB/c mice deficient in AID (pBxAicda-/-).	pristane	65-73	BCL2-like 1	Mus musculus	82-88
17968932-11	2007	The clinical and serologic manifestations observed in TMPD-treated mice were strongly dependent on IFNAR signaling, which is consistent with the association of increased expression of ISGs with lupus-specific autoantibodies and nephritis in humans.	pristane	54-58	interferon (alpha and beta) receptor 1	Mus musculus	99-104
17968932-12	2007	CONCLUSION: Similar to its proposed role in human SLE, signaling via the IFNAR is central to the pathogenesis of autoantibodies and glomerulonephritis in TMPD-induced lupus.	pristane	154-158	interferon alpha and beta receptor subunit 1	Homo sapiens	73-78
17576695-4	2007	METHODS: Eight-week-old C57Bl/10 (B10, H-2(b)) mice received a single intraperitoneal injection of 0.5 ml of Pristane.	pristane	109-117	granzyme C	Mus musculus	24-37
17329308-0	2007	Cia25 on rat chromosome 12 regulates severity of autoimmune arthritis induced with pristane and with collagen.	pristane	83-91	Collagen induced arthritis QTL 25	Rattus norvegicus	0-5
17122779-0	2007	Slc11a1 (formerly NRAMP1) gene modulates both acute inflammatory reactions and pristane-induced arthritis in mice.	pristane	79-87	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	Mus musculus	18-24
17088564-6	2006	Kv1.3 inhibitors ameliorate pristane-induced arthritis in rats and reduce the incidence of experimental autoimmune diabetes in diabetes-prone (DP-BB/W) rats.	pristane	28-36	potassium voltage-gated channel subfamily A member 3	Homo sapiens	0-5
16681036-5	2006	lipopolysaccharide (LPS; endotoxin) injection in pristane-primed chronic inflammation ICR mice characterized by a lupus-like syndrome.	pristane	49-57	toll-like receptor 4	Mus musculus	20-23
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	171-179	interleukin 6	Mus musculus	48-52
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	171-179	interleukin 10	Mus musculus	54-59
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	171-179	interferon gamma	Mus musculus	64-73
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	171-179	interleukin 6	Mus musculus	107-111
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	171-179	interferon gamma	Mus musculus	116-125
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	171-179	toll-like receptor 4	Mus musculus	159-162
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	171-179	tumor necrosis factor	Mus musculus	298-307
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	206-214	toll-like receptor 4	Mus musculus	159-162
16681036-7	2006	And levels of BAL TNF-alpha, IL-6 and IL-10 were significantly enhanced 72 h in LPS-exposed pristane-primed mice compared with pristane-primed controls.	pristane	92-100	tumor necrosis factor	Mus musculus	18-27
16681036-7	2006	And levels of BAL TNF-alpha, IL-6 and IL-10 were significantly enhanced 72 h in LPS-exposed pristane-primed mice compared with pristane-primed controls.	pristane	92-100	interleukin 6	Mus musculus	29-33
16681036-7	2006	And levels of BAL TNF-alpha, IL-6 and IL-10 were significantly enhanced 72 h in LPS-exposed pristane-primed mice compared with pristane-primed controls.	pristane	92-100	interleukin 10	Mus musculus	38-43
16681036-7	2006	And levels of BAL TNF-alpha, IL-6 and IL-10 were significantly enhanced 72 h in LPS-exposed pristane-primed mice compared with pristane-primed controls.	pristane	92-100	toll-like receptor 4	Mus musculus	80-83
16681036-7	2006	And levels of BAL TNF-alpha, IL-6 and IL-10 were significantly enhanced 72 h in LPS-exposed pristane-primed mice compared with pristane-primed controls.	pristane	127-135	toll-like receptor 4	Mus musculus	80-83
16681036-8	2006	Also, LPS significantly induced the increased in vitro production of TNF-alpha, IL-6 and IL-10 by lung cells obtained from LPS-exposed pristane-primed mice compared with LPS-exposed normal mice.	pristane	135-143	toll-like receptor 4	Mus musculus	6-9
16681036-8	2006	Also, LPS significantly induced the increased in vitro production of TNF-alpha, IL-6 and IL-10 by lung cells obtained from LPS-exposed pristane-primed mice compared with LPS-exposed normal mice.	pristane	135-143	tumor necrosis factor	Mus musculus	69-78
16681036-8	2006	Also, LPS significantly induced the increased in vitro production of TNF-alpha, IL-6 and IL-10 by lung cells obtained from LPS-exposed pristane-primed mice compared with LPS-exposed normal mice.	pristane	135-143	interleukin 6	Mus musculus	80-84
16681036-8	2006	Also, LPS significantly induced the increased in vitro production of TNF-alpha, IL-6 and IL-10 by lung cells obtained from LPS-exposed pristane-primed mice compared with LPS-exposed normal mice.	pristane	135-143	interleukin 10	Mus musculus	89-94
16681036-8	2006	Also, LPS significantly induced the increased in vitro production of TNF-alpha, IL-6 and IL-10 by lung cells obtained from LPS-exposed pristane-primed mice compared with LPS-exposed normal mice.	pristane	135-143	toll-like receptor 4	Mus musculus	123-126
16681036-8	2006	Also, LPS significantly induced the increased in vitro production of TNF-alpha, IL-6 and IL-10 by lung cells obtained from LPS-exposed pristane-primed mice compared with LPS-exposed normal mice.	pristane	135-143	toll-like receptor 4	Mus musculus	123-126
16259568-5	2005	Administered after pristane, DNA-hsp65 downregulated arthritis induction in AIRmax animals.	pristane	19-27	heat shock protein 1 (chaperonin)	Mus musculus	33-38
16565497-7	2006	Expression of the type I interferon (IFN-I)-inducible genes Mx1, IRF7, IP-10, and ISG-15 was greatly increased in TMPD- versus mineral oil-induced lipogranulomas.	pristane	114-118	MX dynamin-like GTPase 1	Mus musculus	60-63
16565497-7	2006	Expression of the type I interferon (IFN-I)-inducible genes Mx1, IRF7, IP-10, and ISG-15 was greatly increased in TMPD- versus mineral oil-induced lipogranulomas.	pristane	114-118	interferon regulatory factor 7	Mus musculus	65-69
16565497-7	2006	Expression of the type I interferon (IFN-I)-inducible genes Mx1, IRF7, IP-10, and ISG-15 was greatly increased in TMPD- versus mineral oil-induced lipogranulomas.	pristane	114-118	chemokine (C-X-C motif) ligand 10	Mus musculus	71-76
16565497-7	2006	Expression of the type I interferon (IFN-I)-inducible genes Mx1, IRF7, IP-10, and ISG-15 was greatly increased in TMPD- versus mineral oil-induced lipogranulomas.	pristane	114-118	ISG15 ubiquitin-like modifier	Mus musculus	82-88
16394006-9	2006	These data suggest that the in vivo administration of a non-antigenic adjuvant, like pristane, activates CD4+ alphabetaT cells that are MHC class II restricted and arthritogenic.	pristane	85-93	Cd4 molecule	Rattus norvegicus	105-108
16259568-7	2005	However, when mice previously injected with pristane were inoculated with DNA-hsp65 or DNAv, the protective effect was significantly correlated with lower IL-6 and IL-12 levels and higher IL-10 levels.	pristane	44-52	heat shock protein 1 (chaperonin)	Mus musculus	78-83
16259568-7	2005	However, when mice previously injected with pristane were inoculated with DNA-hsp65 or DNAv, the protective effect was significantly correlated with lower IL-6 and IL-12 levels and higher IL-10 levels.	pristane	44-52	interleukin 6	Mus musculus	155-159
16259568-7	2005	However, when mice previously injected with pristane were inoculated with DNA-hsp65 or DNAv, the protective effect was significantly correlated with lower IL-6 and IL-12 levels and higher IL-10 levels.	pristane	44-52	interleukin 10	Mus musculus	188-193
15761849-3	2005	Here, we have tested the impact of activating CD1d-restricted natural killer T (NKT) cells on pristane-induced lupus-like autoimmunity in BALB/c and SJL mice.	pristane	94-102	CD1d1 antigen	Mus musculus	46-50
15996187-7	2005	The incidence of nephritis was higher in pristane-treated FcgammaRIIB(-/-) mice than pristane-treated FcgammaRI/III(-/-) and (+/+) mice.	pristane	41-49	Fc receptor, IgG, low affinity IIb	Mus musculus	58-69
15996187-7	2005	The incidence of nephritis was higher in pristane-treated FcgammaRIIB(-/-) mice than pristane-treated FcgammaRI/III(-/-) and (+/+) mice.	pristane	41-49	Fc receptor, IgG, high affinity I	Mus musculus	58-67
15996187-8	2005	Hypergammaglobulinaemia and spontaneous anti-DNA/chromatin autoantibody production were associated with interleukin (IL)-6 over-expression in FcgammaRIIB(-/-) mice and were augmented further by pristane treatment when compared to both FcgammaRI/III(-/-) and (+/+) mice.	pristane	194-202	interleukin 6	Mus musculus	104-122
15996187-8	2005	Hypergammaglobulinaemia and spontaneous anti-DNA/chromatin autoantibody production were associated with interleukin (IL)-6 over-expression in FcgammaRIIB(-/-) mice and were augmented further by pristane treatment when compared to both FcgammaRI/III(-/-) and (+/+) mice.	pristane	194-202	Fc receptor, IgG, low affinity IIb	Mus musculus	142-153
15944295-0	2005	The non-MHC quantitative trait locus Cia5 contains three major arthritis genes that differentially regulate disease severity, pannus formation, and joint damage in collagen- and pristane-induced arthritis.	pristane	178-186	Collagen induced arthritis QTL 5	Rattus norvegicus	37-41
15944295-1	2005	Cia5 is a locus on rat chromosome 10 which regulates the severity of collagen- and pristane-induced arthritis (CIA and PIA).	pristane	83-91	Collagen induced arthritis QTL 5	Rattus norvegicus	0-4
15934098-6	2005	Production of autoantibodies directed against granzyme B substrates in response to pristane was evaluated by Western blotting, immunoprecipitation, and enzyme-linked immunosorbent assay.	pristane	83-91	granzyme B	Mus musculus	46-56
15934098-8	2005	NF90 is uniquely cleaved by granzyme B in vitro; however, pristane immunization still induced anti-NF90 antibodies in granzyme B-deficient mice.	pristane	58-66	interleukin enhancer binding factor 3	Mus musculus	99-103
15934098-8	2005	NF90 is uniquely cleaved by granzyme B in vitro; however, pristane immunization still induced anti-NF90 antibodies in granzyme B-deficient mice.	pristane	58-66	granzyme B	Mus musculus	118-128
15934098-9	2005	Pristane-treated granzyme B-deficient mice also produced antibodies directed against the U1-70-kd antigen, a previously identified granzyme B substrate.	pristane	0-8	granzyme B	Mus musculus	17-27
15934098-9	2005	Pristane-treated granzyme B-deficient mice also produced antibodies directed against the U1-70-kd antigen, a previously identified granzyme B substrate.	pristane	0-8	small nuclear ribonucleoprotein 70 (U1)	Mus musculus	89-94
15934098-9	2005	Pristane-treated granzyme B-deficient mice also produced antibodies directed against the U1-70-kd antigen, a previously identified granzyme B substrate.	pristane	0-8	granzyme B	Mus musculus	131-141
16708425-0	2005	Effects of pristane on cytochrome P450 isozyme expression in rat tissues.	pristane	11-19	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	23-38
16708425-3	2005	Pristane exposure led to tissue specific differences in the CYP isozymes expressed and elicited increased CYP protein expression over 3-methylcholanthrene induced levels in microsomes isolated from liver, Peyer"s Patches, and thymus.	pristane	0-8	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	60-63
16708425-3	2005	Pristane exposure led to tissue specific differences in the CYP isozymes expressed and elicited increased CYP protein expression over 3-methylcholanthrene induced levels in microsomes isolated from liver, Peyer"s Patches, and thymus.	pristane	0-8	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	106-109
16708425-5	2005	The data suggest that pristane treatment affects CYP isozyme expression.	pristane	22-30	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	49-52
15761849-4	2005	Repeated in vivo treatment of pristane-injected BALB/c mice with the NKT cell ligand alpha-galactosylceramide (alpha-GalCer) prior to the onset of florid disease suppressed proteinuria, in a manner that was dependent on CD1d and IL-4 expression.	pristane	30-38	CD1d1 antigen	Mus musculus	220-224
15761849-4	2005	Repeated in vivo treatment of pristane-injected BALB/c mice with the NKT cell ligand alpha-galactosylceramide (alpha-GalCer) prior to the onset of florid disease suppressed proteinuria, in a manner that was dependent on CD1d and IL-4 expression.	pristane	30-38	interleukin 4	Mus musculus	229-233
15639644-4	2005	As in conventional mice, pristane-treated germ-free mice developed peritoneal granulomas and hypergammaglobulinemia with increased IgG2a/IgG1 ratios.	pristane	25-33	immunoglobulin heavy variable V1-9	Mus musculus	131-136
15639644-4	2005	As in conventional mice, pristane-treated germ-free mice developed peritoneal granulomas and hypergammaglobulinemia with increased IgG2a/IgG1 ratios.	pristane	25-33	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	137-141
15639644-5	2005	LPS stimulation induced more IL-6, IL-12, and TNF-alpha, and anti-CD3 induced more IFN-gamma and IL-4 by peritoneal cells from pristane-treated mice vs. control.	pristane	127-135	interferon gamma	Mus musculus	83-92
15639644-5	2005	LPS stimulation induced more IL-6, IL-12, and TNF-alpha, and anti-CD3 induced more IFN-gamma and IL-4 by peritoneal cells from pristane-treated mice vs. control.	pristane	127-135	interleukin 4	Mus musculus	97-101
15315756-1	2004	Chromosome translocations between c-myc and immunoglobulin (Ig) are associated with Burkitt"s lymphoma in humans and with pristane- and IL6-induced plasmacytomas in mice.	pristane	122-130	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	34-39
15936744-2	2005	By using an alternative approach, i.e., linkage analysis using relevant animal models we succeeded in finding the Ncf1 gene residing in the Pia4 quantitative trait locus to be responsible for the severity of pristane induced arthritis in rats.	pristane	208-216	neutrophil cytosolic factor 1	Rattus norvegicus	114-118
15936744-2	2005	By using an alternative approach, i.e., linkage analysis using relevant animal models we succeeded in finding the Ncf1 gene residing in the Pia4 quantitative trait locus to be responsible for the severity of pristane induced arthritis in rats.	pristane	208-216	Pristane induced arthritis QTL 4	Rattus norvegicus	140-144
15075356-0	2004	Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production.	pristane	96-104	prostaglandin E receptor 2 (subtype EP2)	Mus musculus	27-30
15075356-0	2004	Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production.	pristane	96-104	prostaglandin E receptor 4 (subtype EP4)	Mus musculus	35-38
15075356-8	2004	High levels of EPs (EP4/2>EP1>EP3), iNOS, and COX-2 mRNA were expressed in peritoneal macrophages from pristane-treated but not untreated or thioglycolate-treated mice (RT-PCR).	pristane	109-117	prostaglandin E receptor 4 (subtype EP4)	Mus musculus	20-23
15075356-8	2004	High levels of EPs (EP4/2>EP1>EP3), iNOS, and COX-2 mRNA were expressed in peritoneal macrophages from pristane-treated but not untreated or thioglycolate-treated mice (RT-PCR).	pristane	109-117	prostaglandin E receptor 1 (subtype EP1)	Mus musculus	29-32
15075356-8	2004	High levels of EPs (EP4/2>EP1>EP3), iNOS, and COX-2 mRNA were expressed in peritoneal macrophages from pristane-treated but not untreated or thioglycolate-treated mice (RT-PCR).	pristane	109-117	prostaglandin E receptor 3 (subtype EP3)	Mus musculus	36-39
15075356-8	2004	High levels of EPs (EP4/2>EP1>EP3), iNOS, and COX-2 mRNA were expressed in peritoneal macrophages from pristane-treated but not untreated or thioglycolate-treated mice (RT-PCR).	pristane	109-117	nitric oxide synthase 2, inducible	Mus musculus	42-46
15075356-8	2004	High levels of EPs (EP4/2>EP1>EP3), iNOS, and COX-2 mRNA were expressed in peritoneal macrophages from pristane-treated but not untreated or thioglycolate-treated mice (RT-PCR).	pristane	109-117	prostaglandin-endoperoxide synthase 2	Mus musculus	52-57
15075356-14	2004	Synovial cells from mice with pristane-induced arthritis (DBA/1) also expressed EP2/4, and the EP2/4 agonist inhibited TNF-alpha production.	pristane	30-38	prostaglandin E receptor 2 (subtype EP2)	Mus musculus	80-85
15075356-14	2004	Synovial cells from mice with pristane-induced arthritis (DBA/1) also expressed EP2/4, and the EP2/4 agonist inhibited TNF-alpha production.	pristane	30-38	prostaglandin E receptor 2 (subtype EP2)	Mus musculus	95-100
15075356-14	2004	Synovial cells from mice with pristane-induced arthritis (DBA/1) also expressed EP2/4, and the EP2/4 agonist inhibited TNF-alpha production.	pristane	30-38	tumor necrosis factor	Mus musculus	119-128
15087411-5	2004	Abrogation of PCT was caused in part by the striking inhibition of the formation of the inflammatory tissue in which PCT develop (pristane granuloma).	pristane	130-138	calcitonin related polypeptide alpha	Homo sapiens	14-17
15087411-5	2004	Abrogation of PCT was caused in part by the striking inhibition of the formation of the inflammatory tissue in which PCT develop (pristane granuloma).	pristane	130-138	calcitonin related polypeptide alpha	Homo sapiens	117-120
12700664-1	2003	BALB/c mice are susceptible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in the coding region of the p16(INK4a) (p16) tumor suppressor gene that produces a protein with impaired activity.	pristane	50-58	cyclin dependent kinase inhibitor 2A	Mus musculus	147-150
14718649-9	2004	At 3 months, pristane and IFA induced mainly IgG2a, squalene IgG1, and MOs IgG3 and IgM in sera.	pristane	13-21	immunoglobulin heavy variable V1-9	Mus musculus	45-50
14718649-9	2004	At 3 months, pristane and IFA induced mainly IgG2a, squalene IgG1, and MOs IgG3 and IgM in sera.	pristane	13-21	LOC105243590	Mus musculus	61-65
12953096-6	2003	We further show that immunization of younger C57BL/6 TSAd-deficient mice (at age 2 mo) with pristane, a recognized nonspecific inflammatory trigger of lupus, results in more severe glomerulonephritis compared with C57BL/6 controls and the production of high titer ss and ds DNA antibodies of the IgG subclass that are not normally produced by C57BL/6 mice in this model.	pristane	92-100	SH2 domain containing 2A	Mus musculus	53-57
14527177-0	2003	Complete Freund"s adjuvant promotes the increases of IFN-gamma and nitric oxide in suppressing chronic arthritis induced by pristane.	pristane	124-132	interferon gamma	Rattus norvegicus	53-62
14611807-2	2003	In pristane-induced arthritis (PIA) in rats we have previously identified Pia3, on chromosome 6, to be a locus that regulates onset of disease.	pristane	3-11	Pristane induced arthritis QTL 3	Rattus norvegicus	74-78
14624754-2	2003	The isolated fragment covers the Pia6 quantitative trait locus on chromosome 14, which previously has been identified to be linked to chronic pristane induced arthritis (PIA) in gene segregation experiments of an (E3 x DA)F(2)-cross.	pristane	142-150	Pristane induced arthritis QTL 6	Rattus norvegicus	33-37
12917264-8	2003	Moreover, pristane treatment suppressed the production of anti-RHA antibodies when administered prior to the onset of autoantibody production, but enhanced anti-RHA levels when given after the onset of autoantibody production, suggesting that pristane interferes with anti-RHA production at an early stage.	pristane	10-18	DEAH (Asp-Glu-Ala-His) box polypeptide 9	Mus musculus	63-66
12917264-8	2003	Moreover, pristane treatment suppressed the production of anti-RHA antibodies when administered prior to the onset of autoantibody production, but enhanced anti-RHA levels when given after the onset of autoantibody production, suggesting that pristane interferes with anti-RHA production at an early stage.	pristane	10-18	DEAH (Asp-Glu-Ala-His) box polypeptide 9	Mus musculus	161-164
12917264-8	2003	Moreover, pristane treatment suppressed the production of anti-RHA antibodies when administered prior to the onset of autoantibody production, but enhanced anti-RHA levels when given after the onset of autoantibody production, suggesting that pristane interferes with anti-RHA production at an early stage.	pristane	10-18	DEAH (Asp-Glu-Ala-His) box polypeptide 9	Mus musculus	161-164
12917264-9	2003	Large amounts of IgG1 anti-RHA autoantibodies were detected in the sera of xid mice, whereas pristane-induced anti-nRNP/Sm and -Su autoantibodies were almost exclusively IgG2a.	pristane	93-101	immunoglobulin heavy variable V1-9	Mus musculus	170-175
12917264-10	2003	Cytokine production within the peritoneal cavity reflected the predominant isotypes: IL-12 and IFN-gamma predominated in pristane-treated mice, whereas IL-4 and IL-6 were more predominant in untreated xid mice.	pristane	121-129	interferon gamma	Mus musculus	95-104
12917264-11	2003	The spontaneous production of anti-RHA by xid mice and its suppression by pristane treatment at the level of autoantibody induction supports the idea that lupus autoantibodies may be generated through a variety of mechanisms.	pristane	74-82	DEAH (Asp-Glu-Ala-His) box polypeptide 9	Mus musculus	35-38
12911539-5	2003	IL-12p35-deficient (-/-) and control (+/+) BALB/c mice were treated with pristane or phosphate-buffered saline (PBS).	pristane	73-81	interleukin 12a	Mus musculus	0-8
12911539-11	2003	As expected, cytokine balance was skewed toward a Th2 response in pristane-treated IL-12 -/- mice.	pristane	66-74	heart and neural crest derivatives expressed 2	Mus musculus	50-53
12911539-13	2003	In contrast to the abrogation of nephritogenic autoantibodies by the lack of IFN-gamma, such antibodies are induced by pristane in IL-12p35-deficient mice.	pristane	119-127	interleukin 12a	Mus musculus	131-139
12902521-5	2003	Strikingly, inoculation of pristane in wild-type mice resulted in reduced numbers and/or functions of NK T cells and CD1d-expressing dendritic cells.	pristane	27-35	CD1d1 antigen	Mus musculus	117-121
12902521-6	2003	These findings suggest that CD1d may play an immunoregulatory role in the development of lupus in the pristane-induced model.	pristane	102-110	CD1d1 antigen	Mus musculus	28-32
12700664-1	2003	BALB/c mice are susceptible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in the coding region of the p16(INK4a) (p16) tumor suppressor gene that produces a protein with impaired activity.	pristane	50-58	cyclin dependent kinase inhibitor 2A	Mus musculus	151-156
12700664-1	2003	BALB/c mice are susceptible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in the coding region of the p16(INK4a) (p16) tumor suppressor gene that produces a protein with impaired activity.	pristane	50-58	cyclin dependent kinase inhibitor 2A	Mus musculus	159-162
12700664-3	2003	Following pristane treatment, BALB/c p16 mRNA levels in B cells were lower than that in DBA/2 or C.D2-Pctr1, a resistant BALB/c congenic strain that harbors DBA/2 chromatin surrounding the p16 locus.	pristane	10-18	cyclin dependent kinase inhibitor 2A	Mus musculus	37-40
12700664-3	2003	Following pristane treatment, BALB/c p16 mRNA levels in B cells were lower than that in DBA/2 or C.D2-Pctr1, a resistant BALB/c congenic strain that harbors DBA/2 chromatin surrounding the p16 locus.	pristane	10-18	cyclin dependent kinase inhibitor 2A	Mus musculus	102-107
12700664-3	2003	Following pristane treatment, BALB/c p16 mRNA levels in B cells were lower than that in DBA/2 or C.D2-Pctr1, a resistant BALB/c congenic strain that harbors DBA/2 chromatin surrounding the p16 locus.	pristane	10-18	cyclin dependent kinase inhibitor 2A	Mus musculus	189-192
10878381-3	2000	We hypothesized that, as in MRL mice, the lpr and gld mutations might accelerate lupus in pristane-treated mice.	pristane	90-98	Fas (TNF receptor superfamily member 6)	Mus musculus	42-45
12209529-9	2002	Arthritis-modifying effects of Cia4 and Cia6 were, however, detected in pristane-induced and/or Freund"s incomplete adjuvant oil-induced arthritis.	pristane	72-80	Collagen induced arthritis QTL 4	Rattus norvegicus	31-35
12209529-9	2002	Arthritis-modifying effects of Cia4 and Cia6 were, however, detected in pristane-induced and/or Freund"s incomplete adjuvant oil-induced arthritis.	pristane	72-80	Collagen induced arthritis QTL 6	Rattus norvegicus	40-44
11737591-11	2001	CONCLUSIONS: IFN-gamma is essential for the induction of nephritis and anti-DNA/chromatin following pristane exposure in BALB/c mice, suggesting that genetic or environmental factors influencing TH1-TH2 balance could be an important determinant of renal disease in lupus.	pristane	100-108	interferon gamma	Mus musculus	13-22
11737591-11	2001	CONCLUSIONS: IFN-gamma is essential for the induction of nephritis and anti-DNA/chromatin following pristane exposure in BALB/c mice, suggesting that genetic or environmental factors influencing TH1-TH2 balance could be an important determinant of renal disease in lupus.	pristane	100-108	negative elongation factor complex member C/D, Th1l	Mus musculus	195-198
11737591-11	2001	CONCLUSIONS: IFN-gamma is essential for the induction of nephritis and anti-DNA/chromatin following pristane exposure in BALB/c mice, suggesting that genetic or environmental factors influencing TH1-TH2 balance could be an important determinant of renal disease in lupus.	pristane	100-108	heart and neural crest derivatives expressed 2	Mus musculus	199-202
11160188-4	2001	Mice with established collagen- or pristane-induced arthritis developed IgG Abs to BiP.	pristane	35-43	heat shock protein 5	Mus musculus	83-86
11113205-5	2001	Concomitantly, resistant C57BL/6 mice, from which both gene products of the Cdkn2a gene have been eliminated, developed pristane-induced plasma cell tumors over a shorter latency period than the traditionally susceptible BALB/cAn strain.	pristane	120-128	cyclin dependent kinase inhibitor 2A	Mus musculus	76-82
10878381-7	2000	Pristane treatment also decreased lymphoproliferation in B6/lpr mice.	pristane	0-8	Fas (TNF receptor superfamily member 6)	Mus musculus	60-63
10878381-9	2000	In contrast, production of anti-DNA/chromatin Abs was associated with IL-6 overproduction in pristane-treated mice, but not in lpr mice.	pristane	93-101	interleukin 6	Mus musculus	70-74
10799447-9	2000	Furthermore, peritoneal macrophages from silicone- and pristane-treated mice produced higher levels of interleukin-1beta (IL-1beta) and IL-6 than those from PBS-treated mice after lipopolysaccharide stimulation.	pristane	55-63	interleukin 1 beta	Mus musculus	103-120
10865979-2	2000	Similar 5"-C mu/c-myc+ clones were also detected in pristane-induced peritoneal granulomata (a significant source of IL-6 in situ) of three of 13 (13%) conventional BALB/c mice, but not in lymphoid tissues of pristane-treated BALB/c mice, nor in any tissue of untreated BALB/c mice.	pristane	52-60	interleukin 6	Mus musculus	117-121
10865979-4	2000	Taken in conjunction with our previous observation that 5"-C mu/c-myc+ clones are the precursors for pristane-induced BALB/c plasmacytomas, the findings further suggested that IL-6 may play a pivotal role in the early stage of plasmacytoma development, by promoting tumor precursor cells.	pristane	101-109	interleukin 6	Mus musculus	176-180
10799447-9	2000	Furthermore, peritoneal macrophages from silicone- and pristane-treated mice produced higher levels of interleukin-1beta (IL-1beta) and IL-6 than those from PBS-treated mice after lipopolysaccharide stimulation.	pristane	55-63	interleukin 1 beta	Mus musculus	122-130
10799447-9	2000	Furthermore, peritoneal macrophages from silicone- and pristane-treated mice produced higher levels of interleukin-1beta (IL-1beta) and IL-6 than those from PBS-treated mice after lipopolysaccharide stimulation.	pristane	55-63	interleukin 6	Mus musculus	136-140
10383938-0	1999	BALB/c.CBA/N mice carrying the defective Btk(xid) gene are resistant to pristane-induced plasmacytomagenesis.	pristane	72-80	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	41-44
10688850-2	2000	In contrast, mutations of the murine CDKN2A gene predispose BALB/c mice to pristane-induced plasmacytoma.	pristane	75-83	cyclin dependent kinase inhibitor 2A	Mus musculus	37-43
10712662-0	2000	The route of administration of an immunodominant peptide derived from heat-shock protein 65 dramatically affects disease outcome in pristane-induced arthritis.	pristane	132-140	heat shock protein 1 (chaperonin)	Mus musculus	70-91
10712662-1	2000	Previous studies have shown that immunization of mice with an immunodominant epitope from heat-shock protein 65 (hsp 65) (amino acids 261-271) can protect from the development of pristane-induced arthritis (PIA) and this protection is mediated by an antigen-specific T helper type 2 (Th2) cytokine response.	pristane	179-187	heat shock protein 1 (chaperonin)	Mus musculus	90-111
10712662-1	2000	Previous studies have shown that immunization of mice with an immunodominant epitope from heat-shock protein 65 (hsp 65) (amino acids 261-271) can protect from the development of pristane-induced arthritis (PIA) and this protection is mediated by an antigen-specific T helper type 2 (Th2) cytokine response.	pristane	179-187	heat shock protein 1 (chaperonin)	Mus musculus	113-119
10383938-0	1999	BALB/c.CBA/N mice carrying the defective Btk(xid) gene are resistant to pristane-induced plasmacytomagenesis.	pristane	72-80	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	45-48
9574571-1	1998	Previous studies showed that mice with pristane-induced arthritis (PIA) and those protected from the disease by preimmunization with mycobacterial 65-kDa heat shock protein (hsp65) possess raised immune responses to hsp65.	pristane	39-47	heat shock protein 1 (chaperonin)	Mus musculus	216-221
10456660-6	1999	These tumors are induced at about 50% incidence in pristane-primed BALB/c mice by injection of v-raf/v-myc- containing retroviruses and are IL-6 dependent.	pristane	51-59	v-raf-leukemia viral oncogene 1	Mus musculus	95-100
10456660-6	1999	These tumors are induced at about 50% incidence in pristane-primed BALB/c mice by injection of v-raf/v-myc- containing retroviruses and are IL-6 dependent.	pristane	51-59	interleukin 6	Mus musculus	140-144
10193432-2	1999	Two subsets of autoantibodies are induced by pristane: IgG anti-DNA DNA and -chromatin autoantibodies are strongly IL-6-dependent, whereas IgG anti-nRNP/Sm and -Su antibodies are not.	pristane	45-53	interleukin 6	Mus musculus	115-119
9730900-0	1998	Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.	pristane	113-121	interleukin 6	Mus musculus	0-13
9730900-3	1998	The goal of this study was to evaluate the role of IL-6 in autoantibody production in pristane-induced lupus.	pristane	86-94	interleukin 6	Mus musculus	51-55
9730900-5	1998	Pristane induced high levels of immunoglobulin (Ig)G anti-single-stranded DNA, -double-stranded (ds)DNA, and -chromatin antibodies in IL-6(+/+), but not IL-6(-/-) mice by enzyme-linked immunosorbent assay.	pristane	0-8	interleukin 6	Mus musculus	134-138
9730900-10	1998	These results suggest that IgG anti-DNA and chromatin antibodies in pristane-treated mice are strictly IL-6 dependent, whereas induction of anti-nRNP/Sm and Su autoantibodies is IL-6 independent.	pristane	68-76	interleukin 6	Mus musculus	103-107
10396078-16	1999	Pristane treated bcl-2 transgenic C57B1/6 mice remained tumor free, although T(12;15) translocation carrying cells were found in the peritoneal fluid of 4/20 mice 176 days after pristane.	pristane	0-8	B cell leukemia/lymphoma 2	Mus musculus	17-22
9811891-6	1998	In vivo suppression of NF-kappaB by either proteasomal inhibitors or intraarticular adenoviral gene transfer of super-repressor IkappaBalpha profoundly enhanced apoptosis in the synovium of rats with SCW- and pristane-induced arthritis.	pristane	209-217	nuclear factor kappa B subunit 1	Homo sapiens	23-32
9038716-0	1997	Pristane-induced arthritis is CD4+ T-cell dependent.	pristane	0-8	CD4 antigen	Mus musculus	30-33
9290947-1	1997	Immunoglobulin heavy chain (Igh)/Myc recombinations are a hallmark of pristane-induced mouse plasmacytomas but are also frequently found in non-tumorous tissues.	pristane	70-78	immunoglobulin heavy variable 7-1	Mus musculus	0-26
9290947-1	1997	Immunoglobulin heavy chain (Igh)/Myc recombinations are a hallmark of pristane-induced mouse plasmacytomas but are also frequently found in non-tumorous tissues.	pristane	70-78	immunoglobulin heavy variable 7-1	Mus musculus	28-31
9290947-1	1997	Immunoglobulin heavy chain (Igh)/Myc recombinations are a hallmark of pristane-induced mouse plasmacytomas but are also frequently found in non-tumorous tissues.	pristane	70-78	myelocytomatosis oncogene	Mus musculus	33-36
9290947-5	1997	Igh/Myc rearrangements were detected in Peyer"s patch follicles and in the intestinal lamina propria both in normal mice and in mice shortly after pristane treatment.	pristane	147-155	immunoglobulin heavy variable 7-1	Mus musculus	0-3
9290947-5	1997	Igh/Myc rearrangements were detected in Peyer"s patch follicles and in the intestinal lamina propria both in normal mice and in mice shortly after pristane treatment.	pristane	147-155	myelocytomatosis oncogene	Mus musculus	4-7
9207461-2	1997	injections of pristane in hypersusceptible BALB/c.DBA/2-Idh1-Pep3 congenic mice.	pristane	14-22	isocitrate dehydrogenase 1 (NADP+), soluble	Mus musculus	56-60
9207461-2	1997	injections of pristane in hypersusceptible BALB/c.DBA/2-Idh1-Pep3 congenic mice.	pristane	14-22	peptidase C	Mus musculus	61-65
9506583-9	1998	Arthritic (E3 x DA)F2 rats had increased serum concentrations of COMP on days 35 and 49 after pristane injection (P < 0.0001 versus the nonarthritic animals).	pristane	94-102	cartilage oligomeric matrix protein	Rattus norvegicus	65-69
9557160-5	1998	pristane injection, followed by increased IgG1, IgG2a, and IgG2b levels.	pristane	0-8	immunoglobulin heavy constant gamma 2B	Mus musculus	59-64
9378954-0	1997	CD4+ Th2 cells specific for mycobacterial 65-kilodalton heat shock protein protect against pristane-induced arthritis.	pristane	91-99	CD4 antigen	Mus musculus	0-3
9378954-0	1997	CD4+ Th2 cells specific for mycobacterial 65-kilodalton heat shock protein protect against pristane-induced arthritis.	pristane	91-99	heart and neural crest derivatives expressed 2	Mus musculus	5-8
9378954-1	1997	Previous studies showed that mice with pristane-induced arthritis (PIA) and those protected from the disease by preimmunization with mycobacterial 65-kDa heat shock protein (hsp65), possess raised immune responses to hsp65.	pristane	39-47	heat shock protein 1 (chaperonin)	Mus musculus	217-222
9284817-5	1997	Although the pristane-induced inflammatory reaction was less pronounced in IL-6-deficient mice versus their wild-type littermates, both B cell differentiation and plasma cell formation took place, and even morphological evidence of plasma cell transformation was detected, albeit at a low frequency.	pristane	13-21	interleukin 6	Mus musculus	75-79
9341754-4	1997	An in vitro co-incubation system was designed in which splenic lipopolysaccharide (LPS) blasts carrying a phage lambda-derived lacI transgene were exposed to pristane-elicited peritoneal exudate cells (PEC).	pristane	158-166	tissue factor pathway inhibitor	Mus musculus	127-131
9341754-6	1997	The lacI-based transgenic mutation assay proved also useful for assessing mutagenicity in vivo, as demonstrated by the detection of elevated mutant frequencies in the spleen (3-fold) and the inflammatory granuloma (4.7-fold) obtained from pristane-treated mice.	pristane	239-247	tissue factor pathway inhibitor	Mus musculus	4-8
9038716-1	1997	The development of arthritis induced in mice by intraperitoneal injection of the non-antigenic mineral oil pristane (2,6,10,14-tetramethylpentadecane) was shown to depend on the presence of CD4+ T cells.	pristane	117-149	CD4 antigen	Mus musculus	190-193
9038716-7	1997	In addition, hsp 65-immunized mice are resistant to the development of pristane-induced arthritis (PIA).	pristane	71-79	heat shock protein 1 (chaperonin)	Mus musculus	13-19
8757508-0	1996	Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice.	pristane	30-38	interleukin 6	Mus musculus	0-13
8690515-2	1996	We show that ABL-MYC, a plasmacytomagenic retrovirus that constitutively expresses v-abl and c-myc, is able to induce plasmacytomas in 100% of athymic BALB/c mice, with or without intraperitoneal pristane pretreatment.	pristane	196-204	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	13-16
8690515-2	1996	We show that ABL-MYC, a plasmacytomagenic retrovirus that constitutively expresses v-abl and c-myc, is able to induce plasmacytomas in 100% of athymic BALB/c mice, with or without intraperitoneal pristane pretreatment.	pristane	196-204	myelocytomatosis oncogene	Mus musculus	17-20
8757508-1	1996	Intraperitoneal injection of pristane induces production of interleukin-6 (IL-6) and either plasmacytosis or plasmacytoma in mice, depending upon the genetic background.	pristane	29-37	interleukin 6	Mus musculus	60-73
8757508-1	1996	Intraperitoneal injection of pristane induces production of interleukin-6 (IL-6) and either plasmacytosis or plasmacytoma in mice, depending upon the genetic background.	pristane	29-37	interleukin 6	Mus musculus	75-79
8757508-3	1996	In the present study we determined whether IL-6 is also required for pristane-induced hyperplasia of normal plasma cells.	pristane	69-77	interleukin 6	Mus musculus	43-47
8757508-4	1996	Pristane was injected intraperitoneally into IL-6-/- and IL-6 wild-type (IL-6+/+) mice.	pristane	0-8	interleukin 6	Mus musculus	45-49
8757508-4	1996	Pristane was injected intraperitoneally into IL-6-/- and IL-6 wild-type (IL-6+/+) mice.	pristane	0-8	interleukin 6	Mus musculus	57-80
8757508-10	1996	These data demonstrate that IL-6 is required for pristane-induced hyperplasia of polyclonal plasma cells in mice.	pristane	49-57	interleukin 6	Mus musculus	28-32
8565293-1	1996	Previous work has indicated that autoimmunity to the mammalian 60-kD heat shock protein (hsp60) may be necessary for the development of pristane-induced arthritis (PIA), a murine model of rheumatoid arthritis.	pristane	136-144	heat shock protein family D (Hsp60) member 1	Homo sapiens	89-94
8643498-1	1996	Injection of mineral oils such as pristane into the peritoneal cavities of BALB/c mice results in a chronic peritonitis associated with high tissue levels of interleukin 6 (IL-6).	pristane	34-42	interleukin 6	Mus musculus	173-177
8643498-3	1996	Levels of both PGE2 and IL-6 are elevated in inflammatory exudates from pristane-treated mice compared with lavage samples from untreated mice.	pristane	72-80	interleukin 6	Mus musculus	24-28
8643498-10	1996	Taken together with the earlier finding that indomethacin diminishes the elevation of IL-6 in pristane-treated mice, the results show that PGE2 can induce IL-6 production in vivo and implicate expression of the Cox-2 gene in the regulation of this cytokine.	pristane	94-102	interleukin 6	Mus musculus	86-90
8643498-10	1996	Taken together with the earlier finding that indomethacin diminishes the elevation of IL-6 in pristane-treated mice, the results show that PGE2 can induce IL-6 production in vivo and implicate expression of the Cox-2 gene in the regulation of this cytokine.	pristane	94-102	interleukin 6	Mus musculus	155-159
8643498-10	1996	Taken together with the earlier finding that indomethacin diminishes the elevation of IL-6 in pristane-treated mice, the results show that PGE2 can induce IL-6 production in vivo and implicate expression of the Cox-2 gene in the regulation of this cytokine.	pristane	94-102	cytochrome c oxidase II, mitochondrial	Mus musculus	211-216
8643498-1	1996	Injection of mineral oils such as pristane into the peritoneal cavities of BALB/c mice results in a chronic peritonitis associated with high tissue levels of interleukin 6 (IL-6).	pristane	34-42	interleukin 6	Mus musculus	158-171
8743293-4	1996	Ascites fluid containing high concentration of VIP monoclonal antibody was produced from pristane-primed BALB/c mice.	pristane	89-97	vasoactive intestinal polypeptide	Mus musculus	47-50
7656217-0	1995	Pristane-induced effects on cytochrome P-4501A, ornithine decarboxylase and putrescine in rats.	pristane	0-8	ornithine decarboxylase 1	Rattus norvegicus	48-71
7656217-3	1995	Increases in both ODC activity and putrescine levels were also observed in pristane treated rats.	pristane	75-83	ornithine decarboxylase 1	Rattus norvegicus	18-21
7656217-4	1995	Collectively, these results indicate that pristane influences cP4501A activity and elicits promoter-like responses as reflected in elevated ODC activity and increased amount of putrescine.	pristane	42-50	ornithine decarboxylase 1	Rattus norvegicus	140-143
8014009-1	1994	Mutants and fusion products of the c-abl gene were used to define some of the molecular requirements for rapid plasmacytoma (PC) and pre-B-lymphoma induction in pristane-treated N-myc transgenic BALB/c mice.	pristane	161-169	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	35-40
7895512-8	1995	We used plasmacytoma XRPC 24 as a model system and found that both IgH alpha and c-myc were poorly repaired, whereas c-abl, a proto-oncogene not related to conventional pristane-induced plasmacytoma-genesis, was efficiently repaired.	pristane	169-177	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	117-122
7721342-5	1995	Development of the syngeneic NS1 plasmacytoma was enhanced by administration of pristane 2 days or 10 days before tumor transplantation.	pristane	80-88	influenza virus NS1A binding protein	Mus musculus	29-32
7554558-2	1995	In this study our aim was to see whether mycobacterial 65 kDa heat shock protein (hsp) could induce the same suppressive effect in experimental Yersinia-associated arthritis as has been reported for arthritides induced by adjuvant, pristane, or streptococcal cell walls (SCW).	pristane	232-240	selenoprotein K	Rattus norvegicus	62-80
8014009-1	1994	Mutants and fusion products of the c-abl gene were used to define some of the molecular requirements for rapid plasmacytoma (PC) and pre-B-lymphoma induction in pristane-treated N-myc transgenic BALB/c mice.	pristane	161-169	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	178-183
8014009-8	1994	Infection of N-myc transgenic bone marrow or spleen cells with A-MuLV in vitro led to the outgrowth of pre-B lymphomas after transplantation to pristane-treated BALB/c recipients.	pristane	144-152	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	13-18
8222314-1	1993	The IgG of patients with rheumatoid arthritis and mice with pristane induced arthritis (PIA) tends to lack the terminal galactose normally on the conserved N-acetylglucosamine linked beta 1-2 to mannose in IgG.	pristane	60-68	hemoglobin, beta adult major chain	Mus musculus	183-191
7514159-8	1994	Flow cytometric analysis revealed an elevation in the T-cell population that expressed CD44, a marker of murine memory T-cells, in spleens from pristane-injected mice.	pristane	144-152	CD44 antigen	Mus musculus	87-91
8031997-6	1994	Mice primed with Pristane were found to have IL-6 in their sera and peritoneal fluid only at a few time points following Pristane treatment; this was determined by IL-6-specific ELISA.	pristane	17-25	interleukin 6	Mus musculus	45-49
8031997-6	1994	Mice primed with Pristane were found to have IL-6 in their sera and peritoneal fluid only at a few time points following Pristane treatment; this was determined by IL-6-specific ELISA.	pristane	17-25	interleukin 6	Mus musculus	164-168
8031997-8	1994	When the Pristane-primed samples were assayed for oncostatin M activity in the A375 melanoma assay, there was oncostatin M activity at various time points.	pristane	9-17	oncostatin M	Mus musculus	50-62
8031997-8	1994	When the Pristane-primed samples were assayed for oncostatin M activity in the A375 melanoma assay, there was oncostatin M activity at various time points.	pristane	9-17	oncostatin M	Mus musculus	110-122
8349317-2	1993	Mice with pristane-induced arthritis have elevated T cell and humoral responses to the 65 kDa heat shock protein derived from Mycobacterium bovis (hsp65) and in common with several other models of autoimmune diseases the incidence of PIA is markedly suppressed by preimmunisation with hsp65 in Freund"s incomplete adjuvant (Thompson et al.	pristane	10-18	heat shock protein 1 (chaperonin)	Mus musculus	147-152
8349317-2	1993	Mice with pristane-induced arthritis have elevated T cell and humoral responses to the 65 kDa heat shock protein derived from Mycobacterium bovis (hsp65) and in common with several other models of autoimmune diseases the incidence of PIA is markedly suppressed by preimmunisation with hsp65 in Freund"s incomplete adjuvant (Thompson et al.	pristane	10-18	heat shock protein 1 (chaperonin)	Mus musculus	285-290
8349317-7	1993	Arthritic CBA/Igb mice given pristane alone develop antibodies to both hsp65 and GroEl (bacterial 60 kDa heat shock proteins) and to hsp58 (the mammalian equivalent).	pristane	29-37	heat shock protein 1 (chaperonin)	Mus musculus	71-76
2019285-2	1991	We report here that injection of pristane into the peritoneal cavities of mice on days 0 and 50, which is known to induce plasmacytomas and arthritis, also induced a rise in the proportion of Gal(O), correlating with a simultaneous rise in the level of IgG antibody binding to the 65-kDa heat-shock protein of Mycobacterium bovis (hsp65).	pristane	33-41	heat shock protein 1 (chaperonin)	Mus musculus	331-336
8425224-0	1993	Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice.	pristane	0-8	interferon gamma	Mus musculus	85-94
8425224-4	1993	In this study, FACS analysis was performed to determine the proportion of myeloid, T. and B cells present in pristane-induced peritoneal exudate (PE), and oil granulomas (OG) of BALB/c, DBA, and CDF1 mice.	pristane	109-117	acyl-CoA synthetase long-chain family member 1	Mus musculus	15-19
8425224-11	1993	In addition, pristane-induced levels of interferon-gamma greater than controls were found in the peritoneal lavages of BALB/c mice at all time points tested but not in DBA or indomethacin-treated BALB/c mice.	pristane	13-21	interferon gamma	Mus musculus	40-56
8425224-12	1993	In contrast, pristane injection increased levels of interleukin-5 in DBA but not BALB/c mice.	pristane	13-21	interleukin 5	Mus musculus	52-65
1432998-4	1992	Treatment with L3T4, a monoclonal antibody specific for murine CD4+ T cells, significantly reduced the incidence of pristane arthritis, and delayed the disease onset.	pristane	116-124	CD4 antigen	Mus musculus	63-66
1432998-5	1992	Monoclonal antibody to Lyt2, the murine CD8+ T cell marker, significantly reduced the levels of rheumatoid factor in pristane injected animals compared with controls, but did not influence the clinical course of PIA.	pristane	117-125	CD8 antigen, alpha chain	Mus musculus	23-27
1581469-2	1992	Arthritic DBA/1 mice had significantly higher serum IL-6 titres than nonarthritic or normal mice at 160 days post pristane injection.	pristane	114-122	interleukin 6	Mus musculus	52-56
1581469-6	1992	An association between serum agalactosyl IgG levels and PEF IL-6 in pristane injected DBA/1 was demonstrated.	pristane	68-76	interleukin 6	Mus musculus	60-64
1516259-7	1992	Here it is clearly demonstrated that the kinetics of IL-6 activity post-pristane injection parallels the kinetics of agalactosyl IgG production.	pristane	72-80	interleukin 6	Homo sapiens	53-57
1611085-4	1992	By using the B9 cell bioassay, it was found that injection of pristane caused a marked and prolonged elevation of interleukin-6 (IL-6) levels in the peritoneal cavities of the mice.	pristane	62-70	interleukin 6	Mus musculus	114-127
1611085-4	1992	By using the B9 cell bioassay, it was found that injection of pristane caused a marked and prolonged elevation of interleukin-6 (IL-6) levels in the peritoneal cavities of the mice.	pristane	62-70	interleukin 6	Mus musculus	129-133
1611085-5	1992	IL-6 was undetectable (less than 15 U/mL) in the peritoneal fluids of unprimed mice and during the first week after injecting pristane.	pristane	126-134	interleukin 6	Mus musculus	0-4
1611085-10	1992	Serum levels of IL-6 were also elevated in pristane-primed mice but were substantially lower than those found in the peritoneal cavity.	pristane	43-51	interleukin 6	Mus musculus	16-20
1611085-12	1992	Experiments performed in vitro showed that pristane-elicited macrophages secreted low levels of IL-6 constitutively and high levels of IL-6 in the presence of lipopolysaccharide.	pristane	43-51	interleukin 6	Mus musculus	96-100
1611085-12	1992	Experiments performed in vitro showed that pristane-elicited macrophages secreted low levels of IL-6 constitutively and high levels of IL-6 in the presence of lipopolysaccharide.	pristane	43-51	interleukin 6	Mus musculus	135-139
1611085-14	1992	Treatment of mice with pristane may provide a model system for studying the inflammatory pathways that control IL-6 levels in vivo.	pristane	23-31	interleukin 6	Mus musculus	111-115
1565479-5	1992	ABL-MYC induced plasmacytomas with or without helper virus, with or without pretreatment of the mice with pristane, and in strains of mice resistant to pristane-induced plasmacytomas.	pristane	106-114	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	0-3
1565479-5	1992	ABL-MYC induced plasmacytomas with or without helper virus, with or without pretreatment of the mice with pristane, and in strains of mice resistant to pristane-induced plasmacytomas.	pristane	152-160	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	0-3
1299349-7	1992	In contrast to the results in experimental AIHA, pristane-induced arthritis (PIA) was effectively prevented by preimmunisation with hsp65, but not with hIgG.	pristane	49-57	heat shock protein 1 (chaperonin)	Mus musculus	132-137
1299349-9	1992	We suggest that the high, sustained production of anti-hsp65 antibodies observed in mice given hsp65 and pristane may play a role in specifically suppressing arthritogenic immune responses in PIA.	pristane	105-113	heat shock protein 1 (chaperonin)	Mus musculus	55-60
2066383-3	1991	Studies to address the possible basis for the pristane-induced changes in the DNA staining characteristics of lymphocytes demonstrated that 1) there were no decreases in the amount of DNA present in the nuclei, 2) nuclei isolated from pristane treated rats were less sensitive to thermal denaturation, as well as DNase I enzymatic digestion, and 3) there were apparent increases in the expression of the H1 histone proteins.	pristane	46-54	deoxyribonuclease 1	Rattus norvegicus	313-320
2066383-3	1991	Studies to address the possible basis for the pristane-induced changes in the DNA staining characteristics of lymphocytes demonstrated that 1) there were no decreases in the amount of DNA present in the nuclei, 2) nuclei isolated from pristane treated rats were less sensitive to thermal denaturation, as well as DNase I enzymatic digestion, and 3) there were apparent increases in the expression of the H1 histone proteins.	pristane	235-243	deoxyribonuclease 1	Rattus norvegicus	313-320
1669738-0	1991	Cellular and humoral reactivity pattern to the mycobacterial heat shock protein hsp65 in pristane induced arthritis susceptible and hsp65 protected DBA/1 mice.	pristane	89-97	heat shock protein 1 (chaperonin)	Mus musculus	80-85
1669738-1	1991	We have analysed the cellular and humoral immunity to the mycobacterial 65 kD heat shock protein (hsp65) in groups of DBA/1 mice with arthritis induced by intraperitoneal injection of the mineral oil pristane.	pristane	200-208	heat shock protein 1 (chaperonin)	Mus musculus	98-103
2102659-6	1990	It was found that the RPC-5 plasmacytoma growth was enhanced only by cells obtained from mice treated with pristane, or by supernatants from cultured PECs and APECs derived from pristane treated mice.	pristane	107-115	polymerase (RNA) III (DNA directed) polypeptide E	Mus musculus	22-27
2183159-0	1990	v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice.	pristane	63-71	v-raf-leukemia viral oncogene 1	Mus musculus	10-15
2253686-8	1990	These findings strongly suggest that autoimmune reactions to an antigen which cross-reacts with hsp65 are generated in pristane-induced arthritis.	pristane	119-127	heat shock protein 1 (chaperonin)	Mus musculus	96-101
2253686-9	1990	It is considered that the autoimmune response is directed to a synovial antigen and that pre-immunization with hsp65 protects the animals from the development of pristane-induced arthritis by altering the specificity or quality of the immune response to this antigen.	pristane	162-170	heat shock protein 1 (chaperonin)	Mus musculus	111-116
2102659-6	1990	It was found that the RPC-5 plasmacytoma growth was enhanced only by cells obtained from mice treated with pristane, or by supernatants from cultured PECs and APECs derived from pristane treated mice.	pristane	178-186	polymerase (RNA) III (DNA directed) polypeptide E	Mus musculus	22-27
30670047-11	2019	LRRK2 deficiency reduced the death rate of pristane treated mice.	pristane	43-51	leucine-rich repeat kinase 2	Mus musculus	0-5
30670047-15	2019	LRRK2 deficiency largely attenuates the pathogenic progress of lupus-like features in pristane-induced mice.	pristane	86-94	leucine-rich repeat kinase 2	Mus musculus	0-5
34077562-7	2021	Importantly, we showed that INF-alpha neutralizing antibody (IFN-alpha-NA) rescued all the changes induced by IFN-alpha in vitro and prevented vascular injury in pristane-induced SLE model in vivo.	pristane	162-170	interferon lambda 3	Mus musculus	28-37
34769174-4	2021	Using the pristane-induced lupus model, we found that mice with defective IFN-lambda receptors (Ifnlr1-/-) showed increased survival rates, decreased lipogranuloma formation and reduced anti-dsDNA autoantibody titers in the early phase of autoimmunity development compared to pristane-treated wild-type mice.	pristane	10-18	interferon lambda receptor 1	Mus musculus	96-102
34769174-5	2021	Moreover, Ifnlr1-/- mice treated with pristane had reduced numbers of inflammatory mononuclear phagocytes and cNK cells in their kidneys, resembling untreated control mice.	pristane	38-46	interferon lambda receptor 1	Mus musculus	10-16
34769174-6	2021	Systemically, circulating B cells and monocytes (CD115+Ly6C+) were reduced in pristane-treated Ifnlr1-/- mice.	pristane	78-86	colony stimulating factor 1 receptor	Mus musculus	49-54
34769174-6	2021	Systemically, circulating B cells and monocytes (CD115+Ly6C+) were reduced in pristane-treated Ifnlr1-/- mice.	pristane	78-86	lymphocyte antigen 6 complex, locus C1	Mus musculus	55-59
34769174-6	2021	Systemically, circulating B cells and monocytes (CD115+Ly6C+) were reduced in pristane-treated Ifnlr1-/- mice.	pristane	78-86	interferon lambda receptor 1	Mus musculus	95-101
34705865-0	2021	The DNA co-vaccination using Sm antigen and IL-10 as prophylactic experimental therapy ameliorates nephritis in a model of lupus induced by pristane.	pristane	140-148	interleukin 10	Mus musculus	44-49
34705865-10	2021	CONCLUSION: The prophylactic co-vaccination of IL-10 with D2 in pristane-induced lupus ameliorates the renal damage maybe by acting as prophylactic DNA tolerizing therapy.	pristane	64-72	interleukin 10	Mus musculus	47-52
35543189-7	2022	The in vivo role of UXT in attenuating the CGAS-STING1 signaling was further confirmed in the mouse model of DNA-virus infection and the TMPD (2,6,10,14-tetramethylpentadecane)-induced murine lupus model.	pristane	137-141	ubiquitously expressed prefoldin like chaperone	Mus musculus	20-23
34282122-7	2021	In terms of mechanism, whole-genome transcriptome profiling was performed by RNA sequencing, revealing that the expression of the transcription factor IRF-8 was higher in M-MDSCs isolated from pristane-induced lupus mice, compared with control mice.	pristane	193-201	interferon regulatory factor 8	Mus musculus	151-156
34142027-0	2021	SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis.	pristane	48-56	secreted acidic cysteine rich glycoprotein	Mus musculus	0-5
34089860-1	2021	C57BL/6 mice with pristane-induced lupus develop macrophage-dependent diffuse alveolar hemorrhage (DAH), which is blocked by treatment with liver X receptor (LXR) agonists and is exacerbated by low IL-10 levels.	pristane	18-26	nuclear receptor subfamily 1, group H, member 3	Mus musculus	140-156
34089860-1	2021	C57BL/6 mice with pristane-induced lupus develop macrophage-dependent diffuse alveolar hemorrhage (DAH), which is blocked by treatment with liver X receptor (LXR) agonists and is exacerbated by low IL-10 levels.	pristane	18-26	nuclear receptor subfamily 1, group H, member 3	Mus musculus	158-161
34089860-1	2021	C57BL/6 mice with pristane-induced lupus develop macrophage-dependent diffuse alveolar hemorrhage (DAH), which is blocked by treatment with liver X receptor (LXR) agonists and is exacerbated by low IL-10 levels.	pristane	18-26	interleukin 10	Mus musculus	198-203
34089860-4	2021	Pristane-induced DAH was prevented by treatment with recombinant Serp-1 and macrophages from Serp1-treated mice exhibited an anti-inflammatory M2-like phenotype.	pristane	0-8	stress-associated endoplasmic reticulum protein 1	Mus musculus	65-71
34089860-4	2021	Pristane-induced DAH was prevented by treatment with recombinant Serp-1 and macrophages from Serp1-treated mice exhibited an anti-inflammatory M2-like phenotype.	pristane	0-8	stress-associated endoplasmic reticulum protein 1	Mus musculus	93-98
34089860-7	2021	We conclude that Serp-1 blocks pristane-induced lung hemorrhage by enhancing LXR-regulated M2 macrophage polarization and KLH4-regulated IL-10 production.	pristane	31-39	stress-associated endoplasmic reticulum protein 1	Mus musculus	17-23
34089860-7	2021	We conclude that Serp-1 blocks pristane-induced lung hemorrhage by enhancing LXR-regulated M2 macrophage polarization and KLH4-regulated IL-10 production.	pristane	31-39	nuclear receptor subfamily 1, group H, member 3	Mus musculus	77-80
34335611-5	2021	Interestingly, B cell-specific deletion of Atg7 led to significant loss of autoreactive memory B cells and reduced autoantibody production in pristane-treated mice.	pristane	142-150	autophagy related 7	Mus musculus	43-47
34290705-0	2021	Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands+ Macrophages via Activating IL-4/STAT6/PD-L2 Signaling.	pristane	38-46	programmed cell death 1	Mus musculus	83-87
34290705-0	2021	Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands+ Macrophages via Activating IL-4/STAT6/PD-L2 Signaling.	pristane	38-46	interleukin 4	Mus musculus	124-128
34203338-7	2021	Under pristane stimulation, alveolar epithelial cells had increased p53, lincRNA-p21 and downstream Bax levels with elevated apoptotic ratios.	pristane	6-14	tumor protein p53	Homo sapiens	68-71
34203338-7	2021	Under pristane stimulation, alveolar epithelial cells had increased p53, lincRNA-p21 and downstream Bax levels with elevated apoptotic ratios.	pristane	6-14	tumor protein p53 pathway corepressor 1	Homo sapiens	73-84
34203338-7	2021	Under pristane stimulation, alveolar epithelial cells had increased p53, lincRNA-p21 and downstream Bax levels with elevated apoptotic ratios.	pristane	6-14	BCL2 associated X, apoptosis regulator	Homo sapiens	100-103
34203338-8	2021	After pristane injection, C57/BL6 mice developed DAH with increased pulmonary expression of p53, lincRNA-p21 and cell apoptosis.	pristane	6-14	transformation related protein 53, pseudogene	Mus musculus	92-95
34203338-8	2021	After pristane injection, C57/BL6 mice developed DAH with increased pulmonary expression of p53, lincRNA-p21 and cell apoptosis.	pristane	6-14	tumor protein p53 pathway corepressor 1	Mus musculus	97-108
34203338-10	2021	Our findings demonstrate increased p53-dependent lncRNA expression with accelerated cell apoptosis in the lungs of SLE-associated DAH patients, and show the therapeutic potential of targeting intra-pulmonary lncRNA expression in a pristane-induced model of DAH.	pristane	231-239	tumor protein p53	Homo sapiens	35-38
35543189-7	2022	The in vivo role of UXT in attenuating the CGAS-STING1 signaling was further confirmed in the mouse model of DNA-virus infection and the TMPD (2,6,10,14-tetramethylpentadecane)-induced murine lupus model.	pristane	143-175	ubiquitously expressed prefoldin like chaperone	Mus musculus	20-23
35571092-0	2022	Qinghao-Biejia Herb Pair Alleviates Pristane-Induced Lupus-Like Disease and Associated Renal and Aortic Lesions in ApoE-/- Mice.	pristane	36-44	apolipoprotein E	Mus musculus	115-119
35468361-4	2022	We thus studied the model of pristane-induced LN and found increasing renal and systemic AREG expression during the course of disease.	pristane	29-37	amphiregulin	Homo sapiens	89-93
35343082-4	2022	In the CD4cre Aim2fl/fl conditional knockout mice, a markedly reduced TFH cell response was observed, with significantly lower levels of serum autoantibodies and proteinuria, as well as profoundly reduced renal IgG deposition in pristane-induced lupus mice.	pristane	229-237	CD4 antigen	Mus musculus	7-10
2770748-1	1989	The hybridoma, 62H3, which secretes a monoclonal IgG2b with anti-HLA-DR specificity, was expanded in pristane-primed BALB/c mice and the antibody was isolated from the ascitic fluid by affinity chromatography on Protein A-Sepharose.	pristane	101-109	immunoglobulin heavy constant gamma 2B	Mus musculus	49-54
35185885-4	2022	Analysis of lung tissue from pristane-treated mice showed genes associated with ER stress and NETosis were increased in a time-dependent manner and reflected the timing of CD11b+Ly6G+ neutrophil accumulation in the lung.	pristane	29-37	integrin alpha M	Mus musculus	172-177
35185885-4	2022	Analysis of lung tissue from pristane-treated mice showed genes associated with ER stress and NETosis were increased in a time-dependent manner and reflected the timing of CD11b+Ly6G+ neutrophil accumulation in the lung.	pristane	29-37	lymphocyte antigen 6 complex, locus G	Mus musculus	178-182
35185885-5	2022	Using precision cut lung slices from untreated mice we observed that neutrophils isolated from the peritoneal cavity of pristane-treated mice could directly induce the expression of genes associated with ER stress, namely Chop and Bip.	pristane	120-128	DNA-damage inducible transcript 3	Mus musculus	222-226
35185885-5	2022	Using precision cut lung slices from untreated mice we observed that neutrophils isolated from the peritoneal cavity of pristane-treated mice could directly induce the expression of genes associated with ER stress, namely Chop and Bip.	pristane	120-128	heat shock protein 5	Mus musculus	231-234
35185885-6	2022	Mice which had myeloid-specific deletion of PAD4 were generated and treated with pristane to assess the involvement of PAD4 and PAD4-dependent NET formation in pristane-induced lung inflammation.	pristane	160-168	MMTV LTR integration site 4	Mus musculus	128-132
35185885-7	2022	Specific deletion of PAD4 in myeloid cells resulted in decreased expression of ER stress genes in the pristane model, with accompanying reduction in IFN-driven genes and pathology.	pristane	102-110	MMTV LTR integration site 4	Mus musculus	21-25
35095344-0	2022	CD4+ T Cells Promote IgG Production in MHC-Independent and ICAM-1-Dependent Manners in Pristane-Induced Lupus Mice.	pristane	87-95	CD4 antigen	Mus musculus	0-3
35095344-0	2022	CD4+ T Cells Promote IgG Production in MHC-Independent and ICAM-1-Dependent Manners in Pristane-Induced Lupus Mice.	pristane	87-95	intercellular adhesion molecule 1	Mus musculus	59-65
35095344-5	2022	Pristane injection induced the increase in IgM levels in both wild-type and T cell-deficient TCRalpha -/- mice whereas IgG, IgG1, and IgG2a production was impaired.	pristane	0-8	T cell receptor alpha chain	Mus musculus	93-101
35095344-5	2022	Pristane injection induced the increase in IgM levels in both wild-type and T cell-deficient TCRalpha -/- mice whereas IgG, IgG1, and IgG2a production was impaired.	pristane	0-8	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	124-128
35095344-5	2022	Pristane injection induced the increase in IgM levels in both wild-type and T cell-deficient TCRalpha -/- mice whereas IgG, IgG1, and IgG2a production was impaired.	pristane	0-8	immunoglobulin heavy variable V1-9	Mus musculus	134-139
35095344-6	2022	When adoptively transferring CD4+ T cells into T cell-deficient mice or coculturing CD4+ T cells and B cells in vitro, it was found that CD4+ T cells derived from pristane-treated mice could help the production of total IgG as well as IgG1/IgG2a in a more efficient manner both in vivo and in vitro.	pristane	163-171	CD4 antigen	Mus musculus	29-32
35095344-6	2022	When adoptively transferring CD4+ T cells into T cell-deficient mice or coculturing CD4+ T cells and B cells in vitro, it was found that CD4+ T cells derived from pristane-treated mice could help the production of total IgG as well as IgG1/IgG2a in a more efficient manner both in vivo and in vitro.	pristane	163-171	CD4 antigen	Mus musculus	84-87
35095344-6	2022	When adoptively transferring CD4+ T cells into T cell-deficient mice or coculturing CD4+ T cells and B cells in vitro, it was found that CD4+ T cells derived from pristane-treated mice could help the production of total IgG as well as IgG1/IgG2a in a more efficient manner both in vivo and in vitro.	pristane	163-171	CD4 antigen	Mus musculus	137-140
35095344-6	2022	When adoptively transferring CD4+ T cells into T cell-deficient mice or coculturing CD4+ T cells and B cells in vitro, it was found that CD4+ T cells derived from pristane-treated mice could help the production of total IgG as well as IgG1/IgG2a in a more efficient manner both in vivo and in vitro.	pristane	163-171	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	235-239
35095344-6	2022	When adoptively transferring CD4+ T cells into T cell-deficient mice or coculturing CD4+ T cells and B cells in vitro, it was found that CD4+ T cells derived from pristane-treated mice could help the production of total IgG as well as IgG1/IgG2a in a more efficient manner both in vivo and in vitro.	pristane	163-171	immunoglobulin heavy variable V1-9	Mus musculus	240-245
35095344-8	2022	Our study thus reveals that CD4+ T cells in pristane-treated mice play important roles in IgG production, which implies the critical roles in the induction of pathological autoantibodies in MHC-independent and ICAM-1-dependent manners.	pristane	44-52	CD4 antigen	Mus musculus	28-31
35095344-8	2022	Our study thus reveals that CD4+ T cells in pristane-treated mice play important roles in IgG production, which implies the critical roles in the induction of pathological autoantibodies in MHC-independent and ICAM-1-dependent manners.	pristane	44-52	intercellular adhesion molecule 1	Mus musculus	210-216
2690079-4	1989	Reactivation of v-raf in J3 is required for efficient plasmacytoma acceleration in pristane-conditioned BALB/cAn mice.	pristane	83-91	v-raf-leukemia viral oncogene 1	Mus musculus	16-21
2824810-2	1987	Myelomonocytic tumors with helper Moloney murine leukemia virus clonally inserted into the c-myb locus were observed in about 10% of pristane-primed BALB/c mice infected with Abelson virus.	pristane	133-141	myeloblastosis oncogene	Mus musculus	91-96
3137564-6	1988	Taken together, these findings support the view that the v-Ha-ras oncogene can cooperate with an activated myc gene in pristane plasmacytomagenesis.	pristane	119-127	myelocytomatosis oncogene	Mus musculus	107-110
6202819-0	1984	Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and abelson virus.	pristane	141-149	myelocytomatosis oncogene	Mus musculus	38-41
6302668-0	1983	Increased expression of myc-related oncogene mRNA characterizes most BALB/c plasmacytomas induced by pristane or Abelson murine leukemia virus.	pristane	101-109	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	24-27
6090069-0	1984	Structural organization of mouse c-myb locus and the mechanism of its rearrangement in ABPL-2 tumor line induced by pristane and Abelson murine leukemia virus.	pristane	116-124	myeloblastosis oncogene	Mus musculus	33-38
6090069-0	1984	Structural organization of mouse c-myb locus and the mechanism of its rearrangement in ABPL-2 tumor line induced by pristane and Abelson murine leukemia virus.	pristane	116-124	filamin C, gamma	Mus musculus	87-91
6090070-0	1984	Disruption and activation of the c-myb locus by M-MULV insertion in plasmacytoid lymphosarcomas induced by pristane and Abelson viruses.	pristane	107-115	MYB proto-oncogene, transcription factor	Homo sapiens	33-38
6656882-3	1983	indicating that in the mouse myeloma XRPC24 originally induced by pristane (2,6,10-14-tetramethylpentadecane) the c-mos gene is rearranged and transcriptionally active, and that it can transform murine fibroblasts in a transfection assay, is therefore of considerable interest.	pristane	66-74	Moloney sarcoma oncogene	Mus musculus	114-119
6656882-3	1983	indicating that in the mouse myeloma XRPC24 originally induced by pristane (2,6,10-14-tetramethylpentadecane) the c-mos gene is rearranged and transcriptionally active, and that it can transform murine fibroblasts in a transfection assay, is therefore of considerable interest.	pristane	76-108	Moloney sarcoma oncogene	Mus musculus	114-119